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ABSTRACT
While several tools have been developed to map axes of variation among individual cells,
no analogous approaches exist for identifying axes of variation among multicellular
biospecimens profiled at single-cell resolution. Developing such an approach is of great
translational relevance and interest, as single-cell expression data are now often collected
across numerous experimental conditions (e.g., representing different drug perturbation
conditions, CRISPR knockdowns, or patients undergoing clinical trials) that need to be
compared. In this work, “Phenotypic Earth Mover's Distance” (PhEMD) is presented as a
solution to this problem. PhEMD is a general method for embedding a “manifold of
manifolds,” in which each datapoint in the higher-level manifold (of biospecimens)
represents a collection of points that span a lower-level manifold (of cells).
PhEMD is applied to a newly-generated, 300-biospecimen mass cytometry drug
screen experiment to map small-molecule inhibitors based on their differing effects on
breast cancer cells undergoing epithelial–mesenchymal transition (EMT). These
experiments highlight EGFR and MEK1/2 inhibitors as strongly halting EMT at an early
stage and PI3K/mTOR/Akt inhibitors as enriching for a drug-resistant mesenchymal cell
subtype characterized by high expression of phospho-S6. More generally, these
experiments reveal that the final mapping of perturbation conditions has low intrinsic
dimension and that the network of drugs demonstrates manifold structure, providing
insight into how these single-cell experiments should be computational modeled and

visualized. In the presented drug-screen experiment, the full spectrum of perturbation
effects could be learned by profiling just a small fraction (11%) of drugs. Moreover,
PhEMD could be integrated with complementary datasets to infer the phenotypes of
biospecimens not directly profiled with single-cell profiling. Together, these findings
have major implications for conducting future drug-screen experiments, as they suggest
that large-scale drug screens can be conducted by measuring only a small fraction of the
drugs using the most expensive high-throughput single-cell technologies—the effects of
other drugs may be inferred by mapping and extending the perturbation space.
PhEMD is also applied to patient tumor biopsies to assess intertumoral
heterogeneity. Applied to a melanoma dataset and a clear-cell renal cell carcinoma
dataset (ccRCC), PhEMD maps tumors similarly to how it maps perturbation conditions
as above in order to learn key axes along which tumors vary with respect to their tumorinfiltrating immune cells. In both of these datasets, PhEMD highlights a subset of tumors
demonstrating a marked enrichment of exhausted CD8+ T-cells. The wide variability in
tumor-infiltrating immune cell abundance and particularly prominent exhausted CD8+ Tcell subpopulation highlights the importance of careful patient stratification when
assessing clinical response to T cell-directed immunotherapies.
Altogether, this work highlights PhEMD’s potential to facilitate drug discovery
and patient stratification efforts by uncovering the network geometry of a large collection
of single-cell biospecimens. Our varied experiments demonstrate that PhEMD is highly
scalable, compatible with leading batch effect correction techniques, and generalizable to
multiple experimental designs, with clear applicability to modern precision oncology
efforts.
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INTRODUCTION
Bulk vs. single-cell profiling
Next-generation sequencing (NGS) has revolutionized the way in which diseases can be
studied. Bulk DNA sequencing (DNA-seq) of germline biospecimens can be leveraged to
discover disease-specific polymorphisms and to investigate disease heritability at an
unprecedented scope and level of detail (1–3). In the setting of cancer, bulk DNA-seq of
liquid- or solid-tumor biopsies has been used to identify somatic alterations (e.g.,
mutations, copy number alterations, and structural variants) that can serve as biomarkers
prognostic of clinical outcomes and predictive of response to therapies (4–9).
Complementarily, bulk RNA-sequencing (RNA-seq) has been used to quantitate gene
expression of protein-coding genes and long non-coding RNAs at the exon level of
resolution. Paired with proteomic assays, NGS approaches have facilitated our
understanding of cellular biology and genomic drivers of disease at all steps of the central
dogma, from DNA to RNA to protein.
While instrumental in building our foundational understanding of cancer
genomics, bulk tumor profiling faces the notable limitation of being unable to resolve
intratumoral heterogeneity. By nature of the sample preparation procedure for bulk NGS,
DNA or RNA fragments are isolated from all cells of a biospecimen in aggregate, and
per-cell read counts cannot be determined. Thus, genomic variants identified via bulk
DNA-seq can only be interpreted as being present in some fraction of profiled cells.
Moreover, it is impossible to determine which of the variants co-occur in a given cancer
cell. The readout of bulk RNA-seq is similarly coarse in that the reported expression of a
given gene represents the average expression across all cells in the biospecimen without
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any consideration of cell-to-cell variation. In practice, when comparing expression values
across biospecimens measured using bulk profiling or when performing association
studies between specific DNA variants and clinical phenotypes, a simplifying assumption
is often made that all (or at least a substantial-enough proportion of) cells in each
biospecimen harbor the genomic variant or gene expression signature of interest. In
reality, this assumption may not always be valid, and bulk measurements may fail to
accurately reflect the expression profiles of individual cells. Bulk profiling may also fail
to detect true biological differences between experimental conditions. The following
example demonstrates these concepts more concretely and highlights the utility of singlecell analytical approaches for accurately characterizing and distinguishing between
multicellular biospecimens.
Consider a multi-specimen dataset consisting of immune cells with collectively
variable expression of CD4 and CD8. Each specimen is comprised of a cell population
that fits one of four distribution patterns, as shown below (Figure 1A). Each Group A
specimen consists of a homogeneous immune cell population characterized by
intermediate expression of both CD4 and CD8. Each Group B specimen consists of two
similarly-abundant immune cell subpopulations: one CD4+ and one CD8+ subpopulation.
Group C specimens consist of a mixture of CD4+, CD8+, and CD4/CD8 double-positive
(DP) immune cells. Group D specimens consist of one CD4+ and one CD8+
subpopulation of roughly equal abundance and one additional rare subpopulation of
CD4/CD8 double-negative (DN) immune cells. Note that these immune cell subtypes
(CD4+, CD8+, DP, and DN) have been reported to exist in normal thymus as well as
various disease states (e.g., breast and hematologic malignancies (10, 11)). The simulated
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experiment consists of 32 specimens in total (eight of each of Groups A-D). By design,
the bulk (average) expression of CD4 and CD8 for each biospecimen is roughly the same
for all biospecimens, regardless of differences in cell subpopulation characteristics.

Figure 1. a) Single-cell profiles of each multicellular biospecimen in a computationally-generated immune
cell dataset. Each point represents a single cell. Groups A-D each have 8 biospecimens that fit the singlecell profile (i.e., are comprised of some combination of the cell subpopulations depicted) for a total of 32
biospecimens. By design, all biospecimens have roughly the same bulk expression (mean across all cells)
of CD4 and CD8. b) Diffusion map embedding generated by embedding a specimen-to-specimen distance
matrix, where pairwise distances between specimens were computed by taking the Euclidean distance
between specimens represented as bulk expression of CD4 and CD8. Bulk expression profiles do not
adequately reflect the biological differences between specimens in this dataset and cannot be used to
distinguish specimens in a biologically meaningful way. c) Diffusion map embedding generated by
embedding a PhEMD distance matrix, which accounts for the single-cell characteristics of each specimen
(see “Overview of PhEMD” in Results section). PhEMD successfully distinguishes specimens with
different single-cell profiles from one another.

Next, consider the aim of relating the 32 specimens to one another in a
biologically meaningful way. This could be done by generating a low-dimensional
embedding that could be visualized to view the similarity of any two specimens relative
to the rest and to identify groups of similar biospecimens. First, consider an approach
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using bulk expression measurements. A biospecimen–biospecimen distance matrix can be
generated by computing pairwise (Euclidean) distances between each pair of
biospecimens, with each biospecimen represented as the average expression of each gene
(i.e., CD4 and CD8) across all cells in the biospecimen. This distance matrix can then be
embedded and visualized in two dimensions using the diffusion map nonlinear
dimensionality reduction approach. The result is an embedding that fails to differentiate
specimens based on biologically important differences. Specifically, specimens of the
same known, ground-truth subtype (i.e., Group A-D) failed to map to similar parts of the
resulting embedding (Figure 1B).
A better approach to comparing these specimens is to compare the presence and
abundance of all single-cell subpopulations in each specimen. I aim to formalize such an
approach in this thesis and demonstrate that it can be used to effectively distinguish
single-cell specimens from one another that cannot be distinguished based on bulk or
average expression patterns. In the above example, the approach yields a final lowdimensional map that vastly outperforms a bulk approach (Figure 1B) and successfully
differentiates specimens based on biologically important differences in cell subpopulation
characteristics and proportions (Figure 1C).
The exploration of cell-to-cell variation within a given biospecimen has been
facilitated by the recent development of single-cell expression profiling (measurement of
gene expression on a per-cell rather than average-across-all-cells level). Early studies
leveraging these technologies have uncovered important insights not previously identified
by bulk profiling. Several studies have highlighted the compositional heterogeneity of
tumors as a mixture of specific cancer and non-malignant (e.g., immune and stromal) cell
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types and have revealed profound cellular heterogeneity among melanoma (12), clear-cell
renal cell carcinoma (ccRCC) (13), and breast cancer cells (14), even within a single
tumor biopsy. Additional studies have used single-cell profiling to better elucidate cell
signaling, differentiation, and reprogramming in the context of cancer (15), aging (16),
and other physiologic and disease processes (17–19). Among else, single-cell profiling is
particularly useful for studying cancer, as cancer is understood to arise from the genomic
mis-programming of a single cell and the downstream sequelae. While the analytical
approaches presented in this work are generalizable to studying many biological
phenomena at a single-cell level, the focus of this thesis will be on leveraging single-cell
technologies to better understand cancer progression, cellular response to
chemotherapies, and the tumor microenvironment.
Approaches to characterizing axes of variation among a collection of cells
As the readout of single-cell expression profiling is highly complex, new computational
tools have been developed in parallel with single-cell profiling techniques in order to
facilitate the extraction of biological insights. A particularly challenging property of
single-cell expression data is its high dimensionality: each biospecimen is comprised of
many cells, each of which is represented by tens to thousands of gene or protein
measurements. The analysis of high-dimensional data, especially in unsupervised or
exploratory settings, often introduces various challenges that are collectively referred to
as the “curse of dimensionality” (20, 21). While the ambient dimension of single-cell data
is often high (equal to the number of genes or proteins measured), the intrinsic
dimension, or minimum number of variables needed to represent the data adequately, is
often much lower. Mapping single-cell data from its ambient dimension to this lower-
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dimensional space is termed “dimensionality reduction,” which is often a critical first
step for learning and visualizing the ways in which cells vary. It is also instrumental in
identifying distinct, biologically meaningful cell subpopulations (e.g., by clustering cells
in the lower-dimensional space). The following subsections provide an overview of
several of the leading dimensionality reduction techniques for learning and visualizing
axes of cell-to-cell variation among a set of cells measured using single-cell expression
profiling. In the below subsections, each “dataset” refers to a heterogeneous cell
population and each “point” represents a single cell, characterized by multiple measured
features (i.e., gene expression values).
Principal Component Analysis (PCA)
Principal component analysis (PCA) is a dimensionality reduction technique that aims to
find new, uncorrelated variables (“principal components”) that successively maximize
variance while minimizing information loss from the original dataset (22). It does so by
performing an orthogonal transformation of the original dataset such that the new
variables are linear combinations of features in the original ambient-dimensional space.
This transformation can be computed as the solution to an eigenvalue/eigenvector
problem, in which principal components are defined as eigenvectors of the covariance
matrix and corresponding eigenvalues represent the proportion of the data variance
explained by the eigenvectors.
PCA is useful in many settings for learning a low-dimensional representation of
the data, although it does make several key assumptions. Firstly, it assumes that the
principal components are appropriately modeled as linear combinations of the original
dimensions. Secondly, PCA assumes that principal components are orthogonal to one
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another. Thirdly, PCA assumes that the input data are scaled and normalized
appropriately prior to application, as the approach is not scale invariant. In the event that
any of these assumptions are violated, PCA may fail to recover optimal axes of variation
in the data. Additionally, by design, PCA prioritizes preserving global structure (i.e.,
distances between faraway points) over local structure (i.e., distances between points
within the same “neighborhood”) when mapping from high- to low-dimensional space.
Thus, the approach is especially sensitive to outliers and measurement noise.
t-Distributed Stochastic Neighbor Embedding (t-SNE)
t-Distributed Stochastic Neighbor Embedding (t-SNE) is a popular dimensionality
reduction approach that preserves local relationships between points when mapping them
from an ambient-dimensional to low-dimensional space (23). Put another way, points that
are close to one another in the original representation of the data are mapped to be close
to one another in the final low-dimensional t-SNE space. Consider two points i and j
denoted by xi and xj respectively in the ambient-dimensional space and yi and yj
respectively in the low-dimensional space. t-SNE first models each point in the ambientdimensional space as a Gaussian probability distribution centered on the actual
coordinates of the point (with a data-dependent variance proportional to a user-specified
“perplexity” value), then computes pairwise similarity between points xi and xj as the
conditional probability Pj|i that xi would select xj as its neighbor if neighbors were
selected in proportion to their probability density under a Gaussian centered at xi (24). An
analogous conditional probability Qj|i is computed between points yi and yj in the lowdimensional t-SNE space, wherein points yi and yj are modeled as Student t-distribution
with one degree of freedom (rather than as a Gaussian distribution). The final low-

8
dimensional embedding is learned through gradient descent by minimizing the KullbackLeibler (KL) divergence between P and Q. In the perfect case, the difference between Pj|i
and Qj|i is zero for all i and j, i.e., the pairwise relationships between points are perfectly
preserved in the ambient and t-SNE dimensions.
Strengths of t-SNE include non-linearity, which renders it superior to linear
approaches such as PCA when applied to curved manifolds, and preservation of local
structure, which reveals subtle differences between similar yet distinct cell
subpopulations. A limitation of t-SNE is its high computational resource demands. In its
exact form, t-SNE has a quadratic time and space complexity, making applications to
datasets larger than 10,000 points often computationally intractable. To mitigate this
issue, various approximations and optimizations have been developed (25–27). Another
limitation is the loss of global structure preservation in the final embedding. t-SNE
effectively identifies neighborhoods of points but generally yields disjoint “clouds” of
points. Thus, continuous (e.g. cellular differentiation) processes and trajectories are often
fragmented in the t-SNE embedding, and relative distances between faraway points or
clusters in the embedding are not preserved (28).
Uniform Manifold Approximation and Projection (UMAP)
Uniform Manifold Approximation and Projection (UMAP) is a dimensionality reduction
approach that has been recently popularized due to its purported advantages over t-SNE
in terms of improved scalability and preservation of both local and global data structure
(29). Similarly to t-SNE, UMAP models points as probability distributions and performs
gradient descent to iteratively “move” points more similar to one another in the ambientdimensional space to be closer to one another in the low-dimensional embedding.
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However, among other minor differences, UMAP omits the normalization of probabilities
used in t-SNE (thus improving runtime) and uses binary cross-entropy instead of KL
divergence as the cost function when comparing relationships between points in the
ambient-dimensional and low-dimensional spaces. UMAP also employs a graph
Laplacian approach to assigning the initial coordinates of the points in low-dimensional
space (prior to the first iteration of gradient descent), in contrast to the random
initialization employed by t-SNE. Early studies have claimed advantages of UMAP over
t-SNE in terms of faster computational runtime, greater preservation of global data
structure, and increased reproducibility of results across different iterations. However,
there is ongoing debate as to whether global structure is truly better preserved using
UMAP than t-SNE and if so, why exactly this may be (30).
Tree-based approaches
Several graph-based approaches have been developed to explicitly model single-cell
expression datasets as an interconnected “web” or “tree” of cells. Particularly aimed at
organizing and visualizing data with intrinsic trajectory structure (e.g., bifurcating
differentiation processes), these approaches typically represent cells as nodes and
relationships between similar cells as edges between nodes. Distances between cells can
then be defined as the shortest path between representative nodes (i.e., minimum number
of edges separating one cell from the other or, in the event of weighted edges, minimum
sum of edge lengths in a path from one cell to the other). Several particular single-cell
tools that employ such an approach include SPADE (31), Wishbone (32), and Monocle2
(33). These approaches are particularly useful for modeling continuous manifolds and for
resolving local neighborhood structure. A key limitation of most tree-based approaches is
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poor scalability. In practice, when working with large datasets, these approaches often
require cell subsampling or prior identification of “landmark points” which may then
collectively comprise a relatively small number of graph nodes. Additionally, the number
of branches recovered in the final tree can vary greatly and is often dependent on userdefined parameters, which may be challenging to tune if the expected number of branches
is not known a priori.
Diffusion maps
Diffusion maps are another nonlinear dimensionality reduction technique based on the
idea that a collection of points (e.g., cells) may be modeled such that a given point (e.g.,
cell) may “transition” to another point (e.g., similar cell state) with a probability
proportional to the known similarity of the two points (34). Diffusion maps first model
points as an interconnected graph, with connectivity between points generally based on
their distance in the ambient-dimensional space (e.g., Gaussian kernel, which prioritizes
preservation of local neighborhood structure). The point-to-point connectivity metric is
then used to represent the probability of “transitioning” from one cell to another in one
step of a random walk. A diffusion process is then performed over a diffusion time t (i.e.,
t-step random walk), wherein the local connectivity of the data is used to reveal the
global geometric structure of the data. The end result is a set of t-step transition
probabilities, which can be used to embed a low-dimensional map that captures both local
and global structure in the data. Diffusion maps are particularly well-suited for modeling
single-cell datasets with known trajectory structure and are modeled on underlying
principles that reflect our intuitive understanding of cellular differentiation processes
(e.g., “transition” from one cell state to the next). Diffusion maps are also attractive for
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their nonlinearity and inherent denoising properties. Limitations of diffusion maps
include high computational runtime and sensitivity to scale parameter σ, which
determines the scale at which the data are visualized (35). In the traditional
implementation of diffusion maps, a fixed σ is used for all points in the dataset, often
imposing a tradeoff between preserving global and local structure with a bias toward
preserving global structure (34, 35). However, subsequent adaptations to the original
implementation proposed by Coifman and Lafon have been developed to better preserve
local structure (36).
PHATE
Potential of Heat-diffusion for Affinity-based Transition Embedding (PHATE) is a
nonlinear dimensionality reduction technique that aims to preserve both local and global
structure when mapping from high- to low-dimensional space (37). Similarly to diffusion
maps, PHATE models cell-to-cell connectivity as one-step transition probabilities in a
random walk model and then performs the diffusion process over diffusion time t to
determine t-step transition probabilities. However, PHATE employs a distance metric
(“potential distance”) between points in the diffusion space distinct from the “diffusion
distance” metric used in diffusion maps. In so doing, PHATE better preserves both local
and global data geometry and yields a more stable embedding than diffusion maps (37).
Characterizing axes of variation among a collection of multicellular cancer
specimens
The multitude of dimensionality reduction techniques described above have been adopted
and adapted to elucidate clusters, patterns, and progressions from high-dimensional
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single-cell data. These techniques all rely on the ability to create a geometry from
datapoints by comparing them on the basis of their features. More specifically, these
techniques often compute a distance between the datapoints (i.e., cells) in order to
organize cells into lower-dimensional embeddings, such as diffusion maps or t-SNE
embeddings, in order to extract biologically meaningful clusters (i.e., cell subtypes) or
trajectories (e.g., cell differentiation pathways) from the data.
However, single-cell experimental designs are becoming increasingly complex,
with data now often collected across numerous experimental conditions to characterize
libraries of drugs, pools of CRISPR knockdowns, or groups of patients undergoing
clinical trials (12, 13, 38–42). The challenge in these experiments is to characterize the
ways in which not only individual cells but also multicellular experimental conditions
vary. Comparing single-cell experimental conditions (e.g., distinct perturbation
conditions or patient samples) is challenging, as each condition is itself high-dimensional,
comprised of a heterogeneous population of cells with each cell characterized by many
gene measurements. Each “datapoint” in such settings should then be a patient or an
experimental condition, which has a collection of measurements associated with it instead
of a single measurement. In this setting, a datapoint is no longer a single set of features
(i.e., a vector) but a collection of observations, each containing its own features (i.e., a
two-dimensional matrix). Thus, existing techniques can no longer be directly applied for
analysis in a straightforward manner.
While two prior studies presented approaches to comparing two single-cell
biospecimens (43, 44), no existing methods address the problem of simultaneously
relating many biospecimens and identifying biologically meaningful ways in which they
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differ. In this work, Phenotypic Earth Mover’s Distance “PhEMD” is presented as a novel
“manifold-of-manifolds” approach to mapping the key axes of variation among a large
set of experimental conditions. PhEMD first leverages the observation that the structure
of a single-cell experimental condition (i.e., multicellular biospecimen) can be well
represented as a low-dimensional manifold (i.e., cell-state embedding) using techniques
such as PHATE or diffusion maps. In this first-level manifold, individual datapoints
represent cells, and distances between cells represent cell-to-cell dissimilarity. PhEMD
models the cellular state space of each experimental condition as a “low-level” manifold
and then models the experimental condition state space as a “higher-level” manifold. The
ultimate goal of PhEMD is to generate this higher-level manifold, in which each
datapoint represents a distinct experimental condition and distances between points
represent biospecimen-to-biospecimen dissimilarity. In this work, the properties and
potentially applications of this final higher-level manifold are explored in depth. Namely,
the manifold can be visualized and clustered to reveal the key axes of variation among a
large set of experimental conditions. Such embeddings can also be extended with
additional data sources to impute experimental conditions not directly measured with
single-cell technologies.
The accuracy of PhEMD is first validated on a synthetic dataset with known
underlying data geometry. PhEMD is then applied to a newly-generated single-cell
dataset to reveal insights into cancer progression and cancer drug-perturbation effects.
Specifically, the dataset represents a large perturbation screen performed on breast cancer
cells undergoing TGFb1-induced epithelial-to-mesenchymal transition (EMT), measured
at single-cell resolution with mass cytometry. EMT is a process that is thought to play a
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role in cancer metastasis, whereby polarized epithelial cells within a local tumor undergo
specific biochemical changes that result in cells with increased migratory capacity,
invasiveness, and other characteristics consistent with the mesenchymal phenotype (45).
In the drug-screen experiment, each perturbation condition consists of cells from the
Py2T breast cancer cell line stimulated simultaneously with TGF-b1 (to undergo EMT)
and a unique kinase inhibitor, with the ultimate goal being to compare the effects of
different inhibitors on our model EMT system. PhEMD is used to embed the space of the
kinase inhibitors to reveal the main axes of variation among all inhibitors with respect to
their effects on breast cancer cells undergoing EMT. Reproducibility of results is assessed
through three biological replicates. Additionally, the drug-effect findings are further
validated by showing that they are consistent with the drug-effect findings of a previously
published study that profiled the drug-target binding specificities of several of the same
drugs as those used in the present drug-screen experiment.
PhEMD is also applied to two distinct single-cell datasets to reveal insights into
variation in the immune cell infiltrate of solid tumors profiled with single-cell resolution.
The first dataset consists of a collection of 17 melanoma samples profiled using singlecell RNA-sequencing (scRNA-seq) and the second is comprised of 75 clear-cell renal cell
carcinoma (ccRCC) samples profiled using mass cytometry. These experiments yield a
low-dimensional map of patient tumors that highlights profound inter-tumoral
heterogeneity with respect to tumor-infiltrating immune cells, demonstrating the potential
utility of PhEMD for disease subtyping and patient stratification (e.g., for immunotherapy
trials or clinical outcomes studies). Collectively, the analyses present a new generalizable
analytical framework for organizing single-cell data and reveal new potential strategies
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for identifying effective cancer therapies.

Hypothesis
A “manifold-of-manifolds” approach to modeling multi-specimen single-cell data can
accurately identify axes of variation among biospecimens and simultaneously reveal
insights into both intra- and inter-specimen heterogeneity.

Specific Aims
Aim 1: Develop a robust tool for uncovering axes of variation among single-cell
biospecimens
Aim 2: Characterize the differing effects of 233 small-molecule inhibitors on breast
cancer epithelial–mesenchymal transition (EMT)
Aim 3: Characterize the immune cell subpopulational variation among melanomas and
among clear-cell renal cell carcinomas (ccRCCs)
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MATERIALS AND METHODS
The PhEMD analytical approach
In single-cell data, each cell is characterized by a set of features, such as protein or
transcript expression levels of genes. The purpose of measuring these expression-based
features for each cell (e.g., via single-cell RNA-seq or mass cytometry) is to answer
biological questions especially related to the cell subpopulations present in a
biospecimen. In particular, the features may be used for defining phenotypes of cells (38,
46), resolving cellular dynamics using transition-process modeling (32, 33, 47), and
studying signaling networks (18, 48). In sum, the features are shared, quantitative
characteristics of cells that may be used to organize a set of cells into a data geometry. An
analogy can be made when attempting to compare single-cell specimens rather than
individual cells. A biospecimen is a collection of cells. In order to compare single-cell
biospecimens for the purpose of organizing a set of cell collections (e.g., different patient
specimens or perturbation conditions), one must first determine useful features for a cell
collection. Previous studies have shown that cell subtypes are highly useful features that
are shared across all specimens and can be quantitatively measured (46, 49). Moreover,
they can be used to represent single-cell specimens efficiently for downstream analyses.
Just as transcript counts can be measured for selected genes in a single cell, so can cell
counts be measured for selected cell subtypes in a cell collection.
In the present work, PHATE is used for the task of defining cell subtypes (37).
PHATE is a diffusion-based single-cell dimensionality reduction technique that both
identifies unique cell subpopulations and relates them to one another on a lowdimensional manifold that can be visualized. Of note, PHATE preserves an information
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theoretic distance between points (i.e., cells) in the diffusion space to derive a stable low
dimensional embedding that reveals local, global, continual, and discrete non-linear
structures in single-cell data. By applying PHATE to an aggregate of cells in a single-cell
experiment, we can represent a biospecimen as the relative frequency of cells in each cell
subtype. This representation of single-cell specimens is consistent with the “signaturesand-weights” representation of multidimensional distributions, first formalized by Rubner
et al. (50), that was found to yield optimal data representation efficiency in other
computer vision applications. In our case, a “signature” can be thought of as a distinct
cell subtype (e.g., memory B-cells or CD8+ effector T-cells), and the corresponding
“weight” represents the proportion of cells in a given specimen assigned to the cell
subtype. However, comparing single-cell specimens represented as such is still a nontrivial task. Many studies represent single-cell specimens as their cell subtype
composition and use known class labels (e.g., normal lung vs. lung adenocarcinoma) to
group specimens and perform class-based comparisons (e.g., identifying cell subtypes
enriched in a disease state) (39, 40). However, this approach is limited to comparing a
few predefined classes of specimens and does not reveal insights into intra-class
heterogeneity. Other studies organize a set of many single-cell specimens based on their
relative frequency of one or a few important cell subtypes (41, 46, 51). However, this
approach requires a priori knowledge of the most important cell subtypes and does not
provide a complete view of specimen-to-specimen dissimilarity, especially in the context
of high intra-specimen cellular heterogeneity.
The ideal metric for comparing specimens should take into account both the
difference in weights of matching bins (e.g., number of epithelial cells) for all bins and
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the dissimilarity of the bins themselves (e.g., intrinsic dissimilarity between epithelial and
mesenchymal cells). As a simple example using the EMT model, for a specimen with
80% mesenchymal, 10% transitional, and 10% epithelial cells, we would expect a
specimen with 50% mesenchymal, 40% transitional, and 10% epithelial cells to be more
similar (closer in distance) than a specimen with 50% mesenchymal, 10% transitional,
and 40% epithelial cells. This would be consistent with our intuitive sense of distance
because 80-10-10 represents that most cells have fully transitioned from epithelial to
mesenchymal states, 50-40-10 represents that most cells have partly or fully transitioned,
and 50-10-40 represents that almost half of the cells have not transitioned at all. Earth
Mover’s Distance (EMD) is a distance metric that mathematically encodes this intuition
and can be used to yield a final singular measure of distance, or dissimilarity, between
two specimens (50). EMD can be conceptualized as the minimal amount of “effort”
needed to move mass (e.g., cells) between bins of one histogram so that its shape matches
that of the other histogram (i.e., all matching bins of two histograms have the same
counts). Mathematically, EMD is defined by the following optimization problem:
/
∑2
,01 ∑-01 +,- .,/
∑2
,01 ∑-01 +,/
Such that ∑2
,01 ∑-01 +,- .,- is minimized subject to the following constraints:
1) +,- ≥ 0
1 ≤ 7 ≤ 8,
1≤9≤:
/
2) ∑-01 +,- ≤ ;<=
1≤7≤8
2
3) ∑,01 +,- = ;>?
1≤9≤:

EMD(%, ') =

Definition 1. Earth Mover’s Distance as an optimization problem.
P = {(p1, ;<@ ), … , (pm, ;<A )}, where pi represents histogram bin i in the initial starting
signature P and ;<= represents the amount of “mass” present in bin i. Similarly,
Q = {(q1, ;>@ ), … , (qn, ;>C )}, where qj represents histogram bin j in the final signature Q
and ;>? represents the amount of “mass” present in bin j. +,- represents the “flow” or
amount of mass moved from bin pi to bin qj. .,- represents the “ground distance”
between bins pi and qj. Constraint 1 ensures that P and Q are the starting and final
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signatures, respectively. Constraints 2 and 3 ensure that no more mass is moved from any
bin pi than is present initially.
EMD has been used in various applications including image retrieval (50, 52),
visual tracking (53), and melodic similarity musical analysis (54): all tasks that require
accurate comparison of multidimensional distributions (analogous to comparing singlecell specimens). Additionally, a prior study demonstrated proof-of-concept that Earth
Mover’s Distance can be used effectively to differentiate flow cytometry specimens of
phenotypically distinct individuals (55). By design, EMD is a distance measure between
probability distributions that is particularly invariant to small shifts in data (i.e., noise or
technical variability) across specimens (50, 55). EMD also gives a “complete” measure of
overall dissimilarity between two specimens, largely attributable to the fact that it takes
into account both the difference in height of corresponding histogram bins between
specimens (e.g., number of epithelial cells) and the concept that certain bins (e.g., cell
subtypes) have a smaller “ground distance” (i.e., are more similar) than others. Including
ground distance between bins in the EMD computation allows us to incorporate the idea
that it requires more “effort” to move mass to a faraway bin than to a nearby bin (i.e., it
requires more effort to convert cells to a more dissimilar cell signature than to a more
similar cell signature). Recall that each cell subtype is associated with various different
datapoints (individual cells assigned to that subtype), so it can be represented as the
centroid of the cluster of cells that comprise it. In our application, we define the ground
distance between two cell subtypes as the manifold distance between the cluster centroids
of the two cell subpopulations representing the subtypes.
EMD is used to compare a pair of single-cell specimens, but the issue remains of
how to relate a large set of samples simultaneously. For this task, we employ a manifold
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learning approach that assumes the intrinsic geometry of the data can conceptually be
modeled as a low dimensional manifold (i.e., a collection of smoothly-varying, locally
low-dimensional data patches), which is derived from the high-dimensional ambient
space of collected features (56). Such methods aim to uncover this intrinsic geometry by
first capturing local neighborhoods, then using them to form a rigid structure of nonlinear
relations in the data, and finally embedding this structure in a low-dimensional (e.g., 2D
or 3D) space via a new set of features that preserve those relations (e.g., as distances).
Local neighborhood (and subsequently global network) structure is learned by first
computing EMD between each pair of single-cell specimens; distances between “nearby”
specimens are then preserved in the final learned manifold.
Leveraging the properties of EMD and manifold learning, we developed PhEMD
as a novel “manifold-of-manifolds” approach to simultaneously relating a large set of
single-cell specimens (Figure 2). PhEMD first aggregates cells from all biospecimens and
applies a single-cell embedding technique (e.g., PHATE) to model the cell-state space
(i.e., “first-level manifold”). PHATE simultaneously identifies all cell subtypes and
relates them in a low-dimensional embedding. After constructing the PHATE cell-state
manifold, PhEMD represents each biospecimen to be compared as a frequency histogram
capturing relative abundance of each cell subtype (i.e., distribution of cells along a
manifold). In the event that subsampling is performed when constructing the PHATE
cell-state manifold, cells are assigned to a subtype using a nearest-neighbor approachA.
PhEMD then uses EMD, incorporating manifold-distance as ground-distance between

A

To assign cell x, which is not initially included in the construction of the PHATE cell-state embedding, to
a cell subtype, we first identify cell y in the initial embedding that was most similar to cell x, i.e. the cell
with the lowest Euclidean distance from cell x. Cell x is then given the same cell subtype assignment as cell
y.
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bins, to compare two relative abundance histograms and derive a single value
representing the dissimilarity between two single-cell specimens. PhEMD computes
EMD pairwise for each pair of specimens to generate a distance matrix representing
specimen–specimen dissimilarity. Finally, using this distance matrix, PhEMD generates a
low-dimensional embedding of single-cell specimens (i.e., “higher-level manifold”) using
diffusion maps to highlight specimen–specimen relationships in the context of overall
network structure (57). Diffusion maps are useful in this case as they learn a nonlinear
mapping of samples from high- to low-dimensional space, capture both local and global
structure, and have intrinsic denoising properties. PhEMD identifies and visualizes
clusters of similar samples based on the compositional similarity of their respective cell
populations.
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Figure 2. a) Flow diagram outlining the sequential steps performed in the PhEMD analysis pipeline. b)
Schematic of the EMD computation, which accounts for both the differences in heights of matching bins
and the intrinsic similarity of bins. c) Visual representation of “ground distance” (dissimilarity) between
cell subtypes. The ground distance between subtypes C-2 and C-6 can be conceptualized as the length of
the dotted path drawn in grey.

Pseudocode for the PhEMD algorithm is shown below in Algorithm 1.
Algorithm 1
1: procedure PhEMD(multispecimen.data)

⊳Map first-level manifold (e.g., cell-state embedding)
2: data.all←aggregateData all specimens(multispecimen.data)
3: first.level.embedding←embedDatapoints(data.all)
4: first.level.clusts←clusterPoints(first.level.embedding)
5: cluster.ground.dists←computeGroundDists(first.level.embedding; first.level.clusts)
⊳Map higher-level manifold (e.g., single-cell specimen embedding)
6: specimen.clus.prop←GetClusterProportions(data.all; first.level.embedding; first.level.clusts)
7: for each pair of specimens si; sj do
8: Dists[i; j]←EMD(cluster.ground.dists; specimen.clus.prop[i]; specimen.clus. prop[j])
9: specimen.embedding←DiffusionMap(Dists)
10: specimen.clusters←ClusterSpecimens(Dists)

Data collection and processing
Py2T cell culture and stimulation
Py2T murine breast cancer cells were obtained from the laboratory of Gerhard
Christofori, University of Basel, Switzerland (58). Cells were tested for mycoplasma
contamination upon arrival and regularly during culturing and before being used for
experiments. Cells were cultured at 37°C in DMEM (Sigma Aldrich), supplemented with
10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, and 100 µg/mL streptomycin, at 5%
CO2. For cell passaging, cells were incubated with TrypLE Select 10X (Life
Technologies) in PBS in a 1:5 ratio (v/v) for 10 minutes at 37°C.
Human recombinant TGF-b1 was purchased from Cell Signaling Technologies as
lyophilized powder and was reconstituted in PBS containing 0.1% carrier protein,
according to the manufacturer’s protocol to 400 ng/mL. The stock solution was kept at -
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20°C until use. For daily treatment, TGF-b1 stock was diluted into medium to 40 ng/mL
working concentration. Following small-molecule inhibitor treatment, 10 µL TGF-b1 was
added to the cells for a final concentration of 4 ng/mL. As a control, PBS containing
carrier protein diluted with growth medium was used.
Small-molecule inhibitors
A library of 234 small molecule kinase inhibitors was purchased from Selleckchem
(Table S1). Small-molecule inhibitors were distributed within the 60 inner wells of five
separate 96-well format deep well blocks with exception of wells within row E, which
contained DMSO. Stock solutions of 2 mM small molecule inhibitor in DMSO were kept
at -80°C until used. For daily treatment, the stock solution was equilibrated at room
temperature for 1 h and then 5 µL of stock solution was added 995 µL of medium. Smallmolecule inhibitor (or DMSO) was added to cells once per day, immediately after the cell
growth media change and before application of TGF-b1. Small-molecule inhibitor
treatment was performed by adding 10 L of pre-diluted reagent to the cells in 80 µL cell
growth medium; this resulted in a final concentration of 1 µM of small-molecule inhibitor
and 0.1% DMSO.
Chronic kinase inhibition screen
For the chronic inhibition experiment, Py2T cells were seeded in 96-well plates (TPP,
Techno Plastic Products AG) with a seeding density of 1800 cells per well in 80 µL of
growth cell media. Only the 60 inner wells were used for analysis. In order to acquire
sufficient sample size, five 96-well plates were used for single condition. After seeding,
cells were allowed to recover for 36 hours to reach 50% confluence. Cells were treated
simultaneously with TGF-b1 or vehicle (PBS) and small-molecule inhibitor or vehicle
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(DMSO) for 5 days, and medium was changed daily. All pipetting procedures were
performed at room temperature using a Biomek FX Laboratory Automation Workstation
(Beckman Coulter) supplied with 96-well pipetting pod.
In addition to experimental conditions treated with small-molecule inhibitors, at
least five “uninhibited” control conditions and five “untreated” control conditions were
included on each 96-well plate. Uninhibited control conditions were those in which TGFb1 was applied to induce EMT in absence of any inhibitor. Untreated control conditions
were those in which neither TGF-b1 nor inhibitor was applied and no EMT was induced.
Cell collection
The cell collection protocol was performed using a Biomek FX Laboratory Automation
Workstation. The cell growth medium was removed using the multiple aspiration
pipetting technique, and cells were washed twice with 37°C PBS. Dissociation reagent
TrypLE Select 10X (Life Technologies) was diluted into PBS at a 1:5 ratio (v/v) was
added to the cells and incubated for 10 min at 37°C. Cells were detached from plates.
Five identically treated 96-well plates were combined into a single deep well block and
were fixed for 10 min with PFA at the final concentration of 1.6% v/v. PFA was blocked
with the addition of 600 µL 10% BSA in CSM. The cells were centrifuged for 5 min at
1040g, at 4°C. The supernatant was removed and the cells were resuspended in 300 µL of
-20°C MeOH. Samples were then transferred onto dry ice and to -80°C storage.
Metal-labeled antibodies
Antibodies were obtained in carrier/protein free buffer and labeled with isotopically pure
metals (Trace Sciences) using MaxPAR antibody conjugation kit (Fluidigm) according to
the manufacturer’s standard protocol. After determining the percent yield by

25
measurement of absorbance at 280 nm, the metal-labeled antibodies were diluted in
Candor PBS Antibody Stabilization solution (Candor Bioscience GmbH) for long-term
storage at 4°C. Antibodies used in this study are listed in Table S2.
Mass-tag cellular barcoding and antibody staining
Cell samples in methanol were washed three times with Cell Staining Media (CSM, PBS
with 0.5% BSA, 0.02% NaN3) and once with PBS at 4°C. The cells were then
resuspended at 1 million cells/mL in PBS containing barcoding reagents (102Pd, 104Pd,
105

Pd, 106Pd, 108Pd, and 110Pd; Fluidigm) were conjugated to bromoacetamidobenzyl-

EDTA (BABE, Dojindo) and two indium isotopes (113In and 115In, Fluidigm) were
conjugated to 1,4,7,10-tetraazacy-clododecane-1,4,7-tris-acetic acid 10-maleimide
ethylacetamide (mDOTA, Mycrocyclics) following standard procedures. Cells and
barcoding reagent were incubated for 30 min at room temperature. Barcoded cells were
then washed three times with CSM, pooled and stained with the metal-conjugated
antibody mix (Table S2) at room temperature for 1 hour. Unbound antibodies were
removed by washing cells three times with CSM and once with PBS. For cellular DNA
staining, an iridium-containing intercalator (Fluidigm) was diluted to 250 nM in PBS
containing 1.6% PFA, added to the cells at 4°C, and incubated overnight. Before
measurement, the intercalator solution was removed and cells were washed with CSM,
PBS, and doubly distilled H2O. After the last wash step, cells were resuspended in MilliQ
H2O to 1 million cells/mL and filtered through a 40-µm strainer.
Mass cytometry data processing
EQ Four Element Calibration Beads (Fluidigm) were added to the cell suspension in a
1:10 ratio (v/v). Samples were measured on a CyTOF1 system (DVS Sciences). The
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manufacturer’s standard operation procedures were used for acquisition at a cell rate of
∼300 cells per second as described previously (59). After the acquisition, all FCS files
from the same barcoded sample were concatenated using the Cytobank concatenation
tool. Data were then normalized and bead events were removed (60). Cell doublet
removal and de-barcoding of cells into their corresponding wells was done using a
doublet-free filtering scheme and single-cell deconvolution algorithm (61). Subsequently,
data were processed using Cytobank (http://www.cytobank.org/). Additional gating on the
DNA channels (191Ir and 193Ir) was used to remove remaining doublets, debris, and
contaminating particles. Final events of interest were exported as .csv files.

In-depth analysis of breast cancer EMT cell-state space and drug-inhibitor manifold
from a single mass cytometry run
CyTOF measurements of cells undergoing unperturbed and perturbed EMT were
generated and processed as described above. Data were then pooled from all
experimental conditions, taking an equal random subsample from each condition to
generate the cell-state embedding. Cell state definitions and relationships were modeled
with PHATE. Subsequently, all cells from all experimental conditions were assigned a
cell subtype using a nearest-neighbor approach.
Next, the cell subtype composition of each inhibition condition (i.e., relative
frequencies of each cell subtype that sum to one for each sample) was determined. Using
this cell subtype frequency-based representation of inhibition conditions, EMD was
computed pairwise between single-cell samples. Euclidean distances between cluster
centroids in the PHATE space (which approximate diffusion-based potential distances
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derived from the expression data native dimensions (37)) were used as a measure of
intrinsic dissimilarity between cell subtypes for the EMD ground-distance matrix. EMD
in this case represented the minimum “effort” required to transform one inhibition
condition to another (conceptually equivalent to the total “effort” needed to move cells
from relatively “overweight” parts of the branched, continuous, EMT cell-state manifold
to relatively “underweight” parts). The EMD between every pair of inhibition conditions
was computed to construct a network of drug inhibition conditions, represented as an
EMD-based distance matrix. The resulting distance matrix was embedded using the
diffusion map approach (as implemented in the ‘destiny’ Bioconductor R package (36))
and partitioned using hierarchical clustering (applied to the untransformed distance
matrix) to highlight inhibitors with significant effects on EMT or similar effects to one
another.

Integrating batch-effect correction to compare 300 EMT inhibition and control
conditions measured in five experimental runs
CyTOF measurements of cells undergoing unperturbed and perturbed EMT were
generated and processed as described in the above sections. Markers shared across all
batches (n = 31) were used for downstream analyses. Data were pooled from all
experimental conditions on a per-batch basis. Expression values were then linearly scaled
for each gene to ensure all values were positive and in the same range across batches.
After this initial normalization, an equal random subsample of cells from each batch
(20,000 x 5) was used as the input for canonical correlation analysis (CCA) (62). CCA
mapped expression data from each batch into an aligned, 8-dimensional space shared by
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all batches. The cell state manifold and cell subtype definitions were modeled by
applying the PHATE dimensionality reduction and clustering method to the eight
dimensions of the CCA-aligned space as input.
All cells from all experimental conditions were assigned a cell subtype using a
nearest-neighbor approach. Next, the cell subtype composition of each inhibition
condition (i.e., relative frequencies of each cell subtype that sum to one for each sample)
was determined. Using this cell subtype-based representation of inhibition conditions,
EMD was computed pairwise between single-cell samples. The ground distance (i.e.
intrinsic dissimilarity) between cell subtypes was defined as the Euclidean distance
between their respective centroids in the three-dimensional PHATE space. The resulting
specimen-to-specimen distance matrix was embedded using the ‘destiny’ Bioconductor R
package (36) and partitioned using hierarchical clustering (applied to the untransformed
distance matrix) to identify 13 clusters of inhibitors with similar effects on EMT.

Intrinsic dimensionality analysis of the EMT perturbation state space
The bias-corrected maximum likelihood estimator approach was used to assess the
intrinsic dimensionality of the EMT perturbation state space (63). The specimen-tospecimen distance matrix for the 300 samples was computed as described above and the
intrinsic dimensionality of this embedding was estimated using the ‘ider’ R package (64).
Intrinsic dimensionality was estimated over a range of values for knn parameter F from 1
through 100. The final value of intrinsic dimensionality was determined by examining the
stable estimated value across a range of sufficiently large values for F (defined as >30).
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Imputing the effects of inhibitions based on a small measured dictionary
A previously published sampling technique for identifying landmark points of an
embedding was applied to assess whether the network geometry of all 300 inhibition and
control conditions could be captured using a smaller subset of conditions (65). The
technique, called “incompletely pivoted QR-based (ICPQR) dimensionality reduction,”
learns a concise embedding of a large collection of datapoints by identifying a subset of
“landmark points” that collectively capture the geometry of the full collection of samples.
The fundamental concept is that these H landmark points comprise an H-dimensional
subspace and that all other existing and new points can be mapped in relation to these.
ICPQR identifies the concise “landmark point” dictionary based on known pairwise
distances between samples (e.g., our EMD-based distance matrix of sample-to-sample
distances). The ICPQR procedure was applied as follows: first, the PhEMD distance
matrix containing pairwise distances between our 300 experimental conditions was
converted to an affinity matrix using a Gaussian kernel (I = 2) and Markov-normalized
to obtain probabilities. The (ICPQR) dimensionality reduction technique was then
applied to this affinity matrix, using a K distortion parameter of 0.01, to identify 34
landmark points. To assess whether the 34 landmark points adequately captured the
geometry of the full collection of 300 samples, the landmark points identified were then
used to impute the geometric coordinates of the remaining (non-landmark) points using
the out-of-sample extension technique associated with ICPQR (65). The result was a 34dimensional embedding of all 300 samples. We computed a 300x300 distance matrix
based on the pairwise Euclidean distances between samples in this 34-dimensional space
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and then embedded it using the ‘destiny’ Bioconductor R package (36).

Incorporating drug-target binding specificity data to extend the PhEMD embedding
and predict the effects of unmeasured inhibitors on TGFβ-induced EMT
We hypothesized that the influence of additional inhibitors on TGFβ-induced EMT could
be predicted based on knowledge of inhibitor–inhibitor similarity from another data
source. To test this, we obtained drug-target specificity data from a previously published
experiment for a set of 39 inhibitors that overlapped between our experiment and theirs
(66). Saracatinib, ibrutinib, and dasatinib were selected as three nonspecific Src inhibitors
whose drug-target specificity data were known and whose effects on EMT we wanted to
predict. Next, a PhEMD embedding was generated based on our CyTOF experimental
results (not including the three selected inhibitors). To predict the effects of the three
inhibitors on EMT relatively to other inhibitors in our experiment, we performed
Nystrom extension on the diffusion map embedding. All 39 inhibitors that were found to
have an effect on EMT in our experiment and that had known drug-target specificity
profiles were included in the Nystrom extension. Pairwise distances between each
“extended” point and each existing point in the original diffusion map were required for
Nystrom extension. These distances were based on the similarity of drug-target
specificity profiles between the two inhibitors, defined as (1 − MNO7:P O787QRS7TU)VW ∗ 4
for all pairs of inhibitors with known drug-target specificity profiles. The remaining
pairwise distances were imputed based on known PhEMD-based inhibitor–inhibitor
dissimilarity and known pairwise drug target specificity-based dissimilarity using the
MAGIC imputation algorithm (67).
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A global shift in embedding coordinates between the original diffusion map
(based on PhEMD distances) and the Nystrom extension points (based on normalized
cosine similarity using drug-target specificity data) was observed. This was likely due to
a difference in scale between PhEMD-based distances and cosine similarity-based
distances. Nonetheless, we were able to use the Nystrom extension points alone to predict
the effect of the three selected inhibitors on EMT. First, we visualized the Nystrom
extension embedding to show the predicted relation of the three inhibitors to other
inhibitors with known (measured) effects on EMT. Next, we used partial least squares
regression (‘pls’ R package (68)) to predict the cell subtype relative frequencies that
would result from applying the inhibitors to breast cancer cells undergoing TGFβ1induced EMT. Nystrom extension embedding coordinates were used as the input
variables for the regression model. To validate our findings, we measured the three
selected inhibitors directly using CyTOF and included them along with the rest of the
inhibitors in the PhEMD analysis pipeline. We compared the actual to the predicted cell
subtype relative frequencies and the actual to the predicted embedding coordinates
relative to other similar, “nearby” inhibitors. To assess prediction accuracy, we compared
our prediction error to the prediction error of the null hypothesis modeled by first
randomizing the PhEMD-based and drug target specificity-based distance matrices and
then generating a predictive model in the same way as in the alternative model.
Prediction error was defined as the EMD between the predicted and actual (measured)
cell subtype relative frequency distributions. The null hypothesis was modeled as a
distribution of EMDs generated by randomizing the PhEMD-based and drug target
specificity-based distance matrices 1,000 times and subsequently imputing cell subtype
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frequencies. P-values were computed by performing a permutation test (n=1,000)
comparing our prediction error to that of the empirical null distribution and applying a
one-sided significance test at a significance level of 0.05.
To more comprehensively assess PhEMD as a predictive tool, leave-one-out cross
validation was performed on the 39 inhibitors with known (measured) cell subtype
relative frequencies and drug-target specificity data. For each inhibitor, we constructed a
PhEMD embedding based on known measurements of the 39 others and performed
Nystrom extension to impute the relationship between the inhibitor and the measured
ones. We then constructed a partial least squares regression model using the same input
variables as above to predict the cell subtype relative frequencies of the inhibitor.
Prediction error was defined the same as above (i.e. EMD between predicted and actual
cell subtype relative frequency distributions). The null model was also defined in the
same way as above by randomizing the PhEMD and distance matrices 100 times for the
prediction of each inhibitor. To determine whether our alternative model was effective,
we assessed whether the prediction errors in the alternative model (n=39) were lower
than the EMDs in the null model (n=3,900) using a one-sided Mann-Whitney U-test.

Predicting drug-target binding specificities based on PhEMD results from EMT
perturbation experiment
We hypothesized that if the PhEMD embedding were meaningful, it would have
predictive power. In order to test this, we used the PhEMD embedding of inhibitors to
predict the inhibitors’ drug-target binding specificities. The drug-target binding
specificity data were obtained from a previously published study that used a chemical
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proteomic approach to identify the protein targets of many clinical kinase inhibitors (66).
We chose to predict the profiles of 39 inhibitors that were present in both the drug-target
binding specificity experiment and ours, and that had at least 1 protein target identified by
the binding specificity experiment. Next, we computed a 39-by-39 knn kernel (k=3) using
the PhEMD inhibitor–inhibitor distances and then row-normalized the resulting matrix to
1 to turn it into a Markov operator. We then performed a leave-one-out cross validation,
in which we set one of the inhibitor target values (i.e., drug-target binding specificity
profiles) in the Klaeger et al. data to be unknown. Note that a drug-target binding
specificity profile was represented as a vector of length 270, which represented the
binding specificity between the drug and each of 270 potential protein targets. We
predicted the drug-target binding specificity values using the MAGIC imputation
method (67) with the PhEMD Markov operator as input and a diffusion parameter T of 2.
We computed leave-one-out predictions for each of the 39 inhibitors. To quantify the
performance of our predictive model, we computed Pearson correlation between the
original ground-truth (experimentally measured) target values and the predicted values.
To determine the accuracy of our predictions, we compared our results to a null model, in
which we randomized the PhEMD matrix 1,000 times and each time ran the prediction
using this randomized matrix. Prediction accuracy (Pearson correlations) of our
alternative model (n=39 predictions, one per inhibitor) was compared to that of the null
model (n=39,000 predictions, 1,000 per inhibitor) using a one-sided Mann-Whitney Utest.
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Generation and analysis of dataset with known ground-truth branching structure
To evaluate the accuracy of the PhEMD analytical approach, high-dimensional single-cell
data (‘Synthetic Dataset B’) were generated using Splatter, a previously published tool
designed to simulate single-cell expression data (69). The basic tree structure represented
in Figure 4A was generating using the following Splatter parameters: nGenes=100,
de.prob=0.5, path.from=c(0,0,0,3,3,5,5,7,7,7). Each single-cell sample consisted of 2000
cells sampled from this cell-state manifold at varying degrees of cellular density spread
across the cell-state space. For Samples A-I, cellular density was concentrated in cell
subtypes C-1 through C-9 (constituting the main axis), with 55% of Sample A consisting
of C-1 and C-2 cells and 55% of Sample I consisting of C-8 and C-9 cells. Samples B-H
consisted of progressively fewer cells in the starting cell states (i.e., C-1 and C-2) and
progressively more cells in the terminal cell states (i.e., C-8 and C-9). Samples X, Y, and
Z were enriched for cells in C-10, C-13, and C-14 respectively. Samples J-M were
comprised predominantly of C-11 cells and Samples N-Q were comprised predominantly
of C-12 cells at increasing degrees of cell-type enrichment.
We applied PhEMD to the library-size normalized Splatter data as outlined in
Figure 2. First, the tree structure was modeled by PHATE based on cells aggregated from
all biological specimens. Then, the relative frequency of cells across different cell
subtypes was computed for each specimen. EMD was computed pairwise for all cells
using PHATE distances as a measure of ground-distance between cell subtypes. A final
diffusion map embedding of biospecimens was generated using the ‘destiny’
Bioconductor R package.
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Analysis of melanoma single-cell RNA-sequencing dataset
Data from a prior single-cell RNA-sequencing experiment were downloaded from the
NCBI Gene Expression Omnibus website, accession number GSE72056 (12). These data
contained read-count expression values that were log TPM-normalized values. 2 of the 19
samples were excluded from analysis due to low cell yield of immune cells. Initial feature
selection was performed by selecting 44 features found in the initial publication
characterization of this dataset to distinguish between key cell types (12). The PHATE
model of the cell-state space was constructed using default parameters to identify ten cell
subtypes. The remaining PhEMD analysis pipeline was completed as described in ‘Indepth analysis of breast cancer EMT cell-state space and drug-inhibitor manifold from a
single mass cytometry run’; a final embedding of biopsy samples was generated using the
‘destiny’ Bioconductor R package and partitioned using hierarchical clustering.

Analysis of clear cell renal cell carcinoma dataset
CyTOF data from a recent publication characterizing the immune landscape of clear cell
renal cell carcinoma were downloaded from
https://premium.cytobank.org/cytobank/projects/875 (13). Cell data were filtered and
normalized using the method described in Methods section titled ‘Mass cytometry data
processing’. The PHATE model of the cell-state space was constructed with a diffusion
parameter t = 40 to identify ten cell subtypes. The remaining PhEMD analysis pipeline
was completed as described in ‘In-depth analysis of breast cancer EMT cell-state space
and drug-inhibitor manifold from a single CyTOF experiment’.
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Statistical methods
Statistical tests were performed as detailed in the above subsections. Differences in group
medians were assessed using a Mann-Whitney U-test. Benchmarking of prediction
accuracy (point estimate) against a null distribution was performed using a permutation
(i.e., randomization) test. All statistical comparisons were performed at a two-sided
significance level of 0.05 unless otherwise stated.

Data availability
The mass cytometry data that support the findings of this study are available at
https://community.cytobank.org/cytobank/projects/1296. Any additional data supporting
the findings of this study are available upon request.

Code availability
PhEMD (“Phenotypic Earth Mover’s Distance”) takes as input a list of H matrices
representing H single-cell specimens. An R implementation of PhEMD is publically
available as a Bioconductor R package (package name: ‘phemd’) and can alternatively be
downloaded from https://github.com/KrishnaswamyLab/phemd. Note that the cell-state
space for all analyses presented in this manuscript was modeled using the PHATE
method. However, alternative approaches are viable, and we have provided support for
PHATE (37), Monocle2 (33), and Louvain community detection (as implemented in the
Seurat software package (62)) for this purpose in the R package.
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RESULTS
Overview of PhEMD
PhEMD is a method for embedding a “manifold of manifolds,” i.e., sets of datapoints in
which each datapoint itself represents a collection of points that comprise a manifold. In
the setting of analyzing single-cell data, each datapoint in the “manifold of manifolds”
represents an experimental condition (i.e., single-cell specimen), which is itself
comprised of a heterogeneous mixture of cells that span a cell-state manifold. PhEMD
first embeds each biospecimen as a manifold and then derives a pairwise distance
between the manifolds. Deriving an “higher-level” embedding then involves using these
pairwise specimen-to-specimen distances to find a coordinate system (i.e., axes of
variability) such that each point represents a specimen, and the distance between the
points represents the dissimilarity between specimens. PhEMD derives such an
embedding using the following general steps (Figure 2):
1. Compute a distance between each pair of datasets (i.e., experimental conditions)
as follows:
a) Embed points within each dataset using PHATE (37).
b) Cluster datapoints using spectral clustering.
c) Represent each dataset as a vector of relative cluster proportions.
d) Compute the distance between two datasets using Earth Mover’s Distance
(EMD).
2. Take the distance matrix derived from the previous step and compute a diffusion
map embedding of the data (34).
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When specifically applied to single-cell data, PhEMD leverages PHATE and spectral
clustering to define cell subtypes, EMD to compute pairwise distances between
biospecimens (based on their cell subtype relative abundances), and the diffusion map
approach to generate a final low-dimensional embedding of biospecimens. Pseudocode
and additional details on the PhEMD algorithm can be found in Methods.

Comparing specimens pairwise using Earth Mover’s Distance (EMD)
A critical component of deriving the correct single-cell specimen embedding is
computing accurate specimen-to-specimen distances. Two existing methods for doing so
are cellAlign (43) and sc-UniFrac (44). However, both impose limiting assumptions or
faced scalability issues that are addressed in our implementation of EMD.
cellAlign was designed to compare two experimental conditions (i.e., two
heterogeneous cell populations) by first modeling each condition as an unbranched
trajectory of cells, then assigning a pseudotime value to each cell based on its ordinal
position in the trajectory, and finally computing a distance between the two experimental
conditions as the “cost” of aligning the two pseudotemporal trajectories. By nature of its
implementation, cellAlign cannot be applied to cell populations sampled from branched
cell-state trajectories, as it assumes cells with the same pseudotime value have identical
gene expression profiles (an assumption violated in the setting of branched cell-state
trajectories). Our implementation of EMD does not make such an assumption and is thus
more flexible for analyzing datasets with branched cell-state trajectories.
sc-UniFrac is a different method that was similarly designed to compare two
single-cell experimental conditions but that faces scalability issues. Its memory
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requirements exceed that of a standard laptop (2.5 GHz Intel Core i7 processor, 16 GB
RAM) when attempting to compare experimental conditions containing collectively
greater than 40,000 cells using default parameters. This prevents it from being useful for
analyzing large multi-specimen datasets such as our drug-screen experiment spanning
300 experimental conditions and over 1.7 million cells. In contrast to sc-UniFrac, which
is unable to be run on a laptop to analyze a set of 40,000 cells from two or more
experimental conditions, PhEMD can be successfully run on the same laptop to analyze a
set of over 360,000 cells from 60 experimental conditions in under 10 minutes. In light of
these memory-based limitations of sc-uniFrac, we compared the runtime of our
implementation of EMD to sc-uniFrac using a smaller dataset consisting of 20 single-cell
specimens each containing 500 cells sampled from a cell-state tree (“Synthetic Dataset
A”). The cell-state tree was generated using the Splatter R package and was characterized
by four branches sharing a single branch point. Our implementation of EMD correctly
recovered the known cell-state space of the dataset (Figure 3A) and had faster empiric
runtime than when analyzing datasets including more than 21,000 cells in total (Figure
3B).

Figure 3. a) PHATE embedding of the cell-state space of Synthetic Dataset A colored by cell-subtypes
identified by PHATE. b) Runtime comparison between PHATE and sc-UniFrac applied to datasets of
increasingly larger sample sizes.

In sum, unlike cellAlign, which can only be applied to datasets in which all cells
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across all specimens were mappable to a single unbranched trajectory (e.g., a simple
differentiation process), our approach can be used to compare specimens comprised of
cells sampled from an underlying cell-state manifold that is potentially branched.
Compared to sc-UniFrac, our implementation of EMD is much more scalable, allowing
for the efficient pairwise comparison of multiple specimens as is required to generate a
final embedding containing many single-cell specimens.

Evaluating accuracy of PhEMD in mapping multi-specimen, single-cell dataset with
known ground-truth structure
We first applied PhEMD to simulated single-cell data with known ground-truth structure
to determine whether PhEMD could accurately model both the cellular heterogeneity
within each specimen and the specimen-to-specimen heterogeneity based on cell subtype
relative abundances. The simulated cells lay on a continuous branched trajectory, wherein
progression along a branch represented concurrent changes in gene expression in select
differentially expressed genes (69). The distribution of cell density across branches was
varied between specimens to simulate a heterogeneous multi-specimen dataset. PhEMD
correctly recovered the branched cell-state manifold structure using PHATE (Figure 4AB). The specimen-to-specimen EMD-based comparison and resulting PhEMD embedding
were also found to be accurate (Figure 4C).
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Figure 4. a) Ground-truth tree structure of the cell-state space of Synthetic Dataset B (see Methods for data
parameters). b) PHATE embedding of the cell-state space of Synthetic Dataset B, colored by cell-subtypes
identified by PHATE. Grey dotted line denotes major axis (comprised of cell subtypes C-1 through C-9)
along which density is modulated for biospecimens A–I. c) Diffusion map embedding of biospecimens.
Points colored black and labeled A–I represent samples that have density concentrated at various clusters
along the trajectory from C-1 (“starting state”) and ending at C-9 (“terminal state”) highlighted in grey. The
alphabetical ordering of samples from A–I correspond to increasing intra-sample relative proportions of
starting state to terminal state points. Samples X and Y represent specimens with cells concentrated in
clusters C-13 and C-14 respectively (i.e. highly similar cell subtypes), and Sample Z represents a specimen
with cells concentrated in cluster C-11 (highly dissimilar to cell subtypes C-13 and C-14). d) Relative
frequency histograms representing distribution of cells across different cell subtypes for selected samples
forming a sub-trajectory in the biospecimen embedding.

The accuracy of the final PhEMD biospecimen map was then assessed as follows.
First, we examined the single-cell specimens in which a large number of cells were
concentrated in a single branch. We found that specimens with cellular density
concentrated in branches close to one another on the cell-state manifold (e.g. Samples X
and Y) tended to map to regions close to one another on the biological-specimen
manifold compared to specimens with cellular density concentrated in branches far from
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one another on the cell-state manifold (e.g. Samples X and Z). Next, we examined
Samples A–I: specimens in which cellular density was modulated so that Sample A had
cells mostly in the arbitrary “starting” state of the manifold, Sample I had cells mostly in
an arbitrary “terminal” state, and Specimens B through H had progressively fewer cells in
the “starting” state and more cells in the “terminal” state. We found that in the final
biospecimen embedding, Samples A–I appropriately formed a trajectory and were
ordered based on their intra-specimen relative proportions of “starting state” to “terminal
state” cells. Finally, we examined Samples J-Q: specimens in which point density was
concentrated in intermediate branches diverging from the main trajectory of the cell-state
manifold (i.e., cell subtypes C-11 and C-12). We found that PhEMD correctly mapped
these specimens to distinct branches in the final single-cell specimen embedding and
correctly ordered them in terms of increasing enrichment of the C-11 and C-12 cell types.
Overall, this demonstrated that our approach accurately inferred both the cell-type
frequencies in each specimen and the similarity between cell subtypes.

Assessing the differing effects of selected drug perturbations on EMT in breast
cancer
To study key regulators of epithelial-to-mesenchymal transition (EMT) in breast cancer,
we performed a drug screen consisting of 300 inhibition and control conditions,
collectively inhibiting over 100 unique protein targets in murine breast cancer cells
undergoing TGFβ1-induced EMT (Figure 5, Table S1). These specimens collectively
contained over 1.7 million cells measured in a total of five mass cytometry runs. Time-offlight mass cytometry (CyTOF) was used on day 5 of cell culture to measure the
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concurrent expression of 31 protein markers in each cell (Table S2), and PhEMD was
used to model both the cell-state transition process and the perturbation-effect manifold.
Batch correction was performed using canonical correlation analysis (CCA) prior to
modeling the cell-state and single-cell specimen embeddings in order to analyze all
experimental conditions across all plates simultaneously.

Figure 5. Experimental design for measuring perturbation effects of small molecule inhibitors on TGFβ1induced EMT.

Batch effect correction in multi-run EMT experiment
Batch effect is a well-known problem when comparing data from multiple single-cell
RNA-sequencing (62, 70) or CyTOF (71, 72) experiments. Because of this, single-cell
specimens are ideally processed and measured in a single batch. However, comparing
specimens across experimental runs is still of great interest. In some cases, the sheer
number of specimens makes simultaneous processing impossible. In other cases, the
experimental design (e.g. time-series analysis) precludes sample processing on the same
plate or gene profiling of all specimens simultaneously. In order to enable these sorts of
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experiments, a number of methods have been recently published that correct for batch
effect. We chose canonical correlation analysis (CCA), a new feature of the popular
Seurat package, as our batch correction tool and demonstrated that PhEMD can leverage
existing batch correction methods to compare hundreds of specimens from five
experimental runs.
To assess the presence of batch effect in our multi-plate experiment prior to batch
effect normalization, we performed t-SNE dimensionality reduction on an equal, random
subsample of cells from each batch (Figure 6). Since each batch used the same Py2T
breast cancer cell line and contained a relatively similar mix of inhibition and control
conditions, batches were expected to have more shared than non-shared cell subtypes. If
true, this phenomenon would appear as extensive inter-plate mixing in most regions of
the t-SNE cell state space. This is because most sources of variation in the data were
expected to be attributable not to the plate on which specimens were cultured or CyTOF
run in which specimens were measured, but instead to specimen-specific biology.
Visualizing the t-SNE embedding and coloring cells by their original batch (Figure 6A),
we noticed poor inter-plate mixing. This indicated that batch effect was present in the
unnormalized data.
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Figure 6. t-SNE embedding of cells from multiple CyTOF runs based on gene expression data a) pre- and
b) post-CCA batch correction, with individual cells colored by experimental batch.

We then applied CCA to the expression measurements and ran t-SNE on the
batch-corrected data (Figure 6B). Reassuringly, we noticed that there was strong interplate mixing when coloring cells in the t-SNE embedding by their original plate. This
suggests that CCA effectively corrected for the technical sources of variation that
appeared to be dominating the initial t-SNE embedding based on un-normalized
expression data (Figure 6A). To assess whether batch effect correction not only removed
technical sources of variation but also performed accurate data alignment, we examined
the control conditions present on each plate. Two sets of identical control conditions were
included on each plate: one set consisted of Py2T epithelial cells cultured with neither
TGF-b1 nor drug inhibitor (“untreated controls”), and the other set consisted of Py2T
cells stimulated with TGF-b1 and given no drug inhibitor (“uninhibited controls”). In our
final clustering of specimens, we found that all of the untreated controls from all 5 plates
clustered together and consisted almost entirely of the same epithelial cell population.
Similarly, all of the uninhibited controls from all 5 plates clustered together and consisted
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predominantly of late-transitional and mesenchymal cells. Moreover, inhibitors targeting
the same molecular target tended to group together, irrespective of batch (e.g. Clusters D,
E, F). These findings suggest that CCA accurately aligned the expression data.
Cell-subtype definition via manifold clustering
By design, all cells undergoing EMT were derived from the same homogeneous epithelial
cell population. Thus, a continuous manifold with potentially branched structure (as
modeled by PHATE) was ideal to model the cell-state space. Applied to the batchcorrected expression data, and PHATE identified nine cell subtypes across all
unperturbed and perturbed EMT conditions (Figure 7A-B).
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Figure 7. a) PHATE embedding of cells from all 300 experimental conditions, colored by cell subtype. b)
Heatmap representing log2 protein expression levels for each cell subpopulation representing its respective
cell subtype. c) Diffusion map embedding of control and drug-inhibited conditions, colored by clusters
determined by hierarchical clustering. d) Individual inhibitors assigned to each inhibitor group. Histograms
represent bin-wise mean of relative frequency of each cell subtype for all inhibitors in a given group. The
full list of inhibitors in each group can be found in Table S3.
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C-1 was characterized by the following expression pattern: E-cadherin(hi) bcatenin(hi) CD24(hi) vimentin(lo) CD44(lo). C-5 and C-6 had roughly the opposite expression
profile with respect to the markers described above (Figure 7B). E-cadherin is the
hallmark cell adhesion marker of epithelial cells (73), and vimentin and CD44 are known
mesenchymal markers involved in cell migration (73–76). Moreover, recent studies found
high CD44:CD24 expression to be indicative of breast cancer cell invasiveness and an as
an EMT endpoint, suggestive of mesenchymal properties (77–79). C-3 was characterized
by low-intermediate expression of both E-cadherin and vimentin, and C-4 was
characterized by cells with intermediate levels of E-cadherin and vimentin and increased
expression of p-MEK1/2, p-ERK1/2, p-p38-MAPK, p-GSK-3, and p-NFkB-p65. These
subtypes were consistent with the “hybrid” cancer cells that co-express epithelial and
mesenchymal markers (E+/M+) and simultaneously demonstrate both epithelial and
mesenchymal properties (80–82). Altogether, the subtypes identified by PHATE are
consistent with known epithelial, mesenchymal, and “hybrid” EMT cell phenotypes, and
the trajectory defined by subtypes C-1 through C-6 in our model represent the epithelialto-mesenchymal transition process that one would expect to recover in our dataset.
In addition to modeling the main EMT trajectory, the PHATE cell-state
embedding identified additional cell subtypes mapped to regions of the cell-state
manifold off of the main EMT axis. C-7 and C-8 were mapped close to the C-6
mesenchymal subtype. C-7 was characterized by high expression of vimentin, CD44,
cyclin B1, and pRb, and C-8 was characterized by high expression of vimentin, CD44,
and phospho-S6. C-9 demonstrated high E-cadherin and cleaved caspase-3 expression
and was consistent with an epithelial subpopulation undergoing apoptosis. By analyzing
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our single-cell data with PHATE, which applied no prior assumptions on the intrinsic
geometry of the cell-state embedding, we were able to uncover a more complex,
continuous model of EMT than has been previously reported.
Constructing and clustering the EMD-based drug-inhibitor manifold
After modeling the EMT cell-state space with PHATE, PhEMD mapped the experimental
variable (i.e., multicellular biospecimen) state space as a low-dimensional embedding
(Figure 7C). Hierarchical clustering revealed clusters of inhibitors with similar net effects
on EMT. Moreover, “uninhibited” controls (TGF-b1 applied in absence of any inhibitor)
and “untreated” controls (neither TGF-b1 nor inhibitor applied) were included to
distinguish inhibitors with notable effects on EMT.
The final embedding of drug inhibitors highlighted the variable extent of EMT
that had occurred in the different inhibition conditions (Figure 7C-D). This diffusion map
embedding was low-dimensional with an intrinsic dimensionality of 2.4 (Figure 8),
implying relatively few axes of variation that could be appropriately visualized in three
dimensions.
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Figure 8. Intrinsic dimension of the PhEMD embedding comprised of 300-sample multi-batch EMT
inhibition and control conditions, computed using the maximum likelihood estimation (MLE) approach
over a range of “k” (k-nearest-neighbors parameter) values.

Fourteen inhibitor clusters (Clusters A-N) were identified (Table S3). Cluster A included
the untreated controls and the TGFβ1-receptor inhibitor condition, each of which
consisted almost entirely of epithelial cells (C-1). These were experimental conditions in
which EMT was effectively not induced. On the other hand, Cluster I included all
uninhibited control conditions and inhibitors ineffective at modulating EMT; inhibitors in
this cluster were found to have mostly mesenchymal (C-6) cells. Clusters B through H
included inhibitors that had generally decreasing strength with respect to halting EMT
(Figure 7C-D). The inhibitors in Clusters J and K formed a prominent trajectory off the
main EMT-extent trajectory in the inhibitor embedding (Figure 7C). Clusters J and K
were enriched in cell subtype C-8, with Cluster K inhibitors inducing cell populations
that were almost entirely comprised of C-8 cells.
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All of the Cluster K inhibitors targeted PI3K, Akt, or mTOR protein kinases –
three members of a well-characterized pathway. Compared to the predominant
mesenchymal subtype observed in the uninhibited controls (C-6), C-8 was comprised of
cells with similarly high expression of vimentin and CD44 and markedly higher
expression of phospho-S6 (Figure 7). This expression profile was consistent with an
alternative-mesenchymal EMT subtype. Examining the cell yield of these inhibitors
compared to the respective uninhibited control conditions in their respective batches, we
found that the cell yield of the Cluster K inhibitors was on average 60% lower than the
TGFβ1-only controls (Table S4). Based on these findings and a prior report that high
expression of phospho-S6 was associated with resistance to PI3K inhibitors (83), the C-8
subtype is likely a mesenchymal cell population relatively resistant to inhibition of the
PI3K-Akt-mTOR axis.
In general, small molecule inhibitors that had the same molecular target tended to
cluster together, consistent with the intuitive notion that drugs with similar mechanisms
of action likely have similar net effects on a given cell population (e.g. Cluster C, Cluster
G). However, several inhibitors with the same reported primary target generated different
resulting single-cell profiles and were clustered into different inhibitor clusters. This
phenomenon may be due to differences in inhibitor potency and differences in off-target
effects.

Analyzing EMT perturbations measured in a single CyTOF run
An analysis of a subset of 60 inhibition and control conditions measured in the same
mass cytometry run (and hence not requiring batch normalization) was performed to
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assess whether applying PhEMD to batch-normalized and single-batch expression data
would yield consistent results. Three replicates involving independent cell culture
experiments measured in distinct mass cytometry runs were analyzed to demonstrate
reproducibility of results.
Cell subtype definition via manifold clustering
Our model of the cell-state space identified eight unique cell subtypes across all
unperturbed and perturbed EMT specimens (Figure 9A-B). These included the starting
epithelial subtype (C-1), main mesenchymal subtype (C-5), and transitional subtypes on
the major EMT-axis (C-2 through C-4). C-1 was characterized by the following
expression pattern: E-cadherin(hi) β-catenin(hi) CD24(hi) vimentin(lo) CD44(lo). C-4 and C-5
had roughly the opposite expression profile with respect to the markers described above
(Figure 9). C-6 through C-8 had expression profiles consistent with C-7 through C-9 in
our multi-batch experiment (Figure 7B, Figure 9B). Altogether, the cell subtypes
recovered in the single-batch and batch-normalized experiments were consistent with one
another and with known EMT cell subtypes.
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Figure 9. a) PHATE embedding of cells from all conditions of a single CyTOF run representing perturbed
EMT cell state landscape, colored by cell subtype determined using spectral clustering. b) Heatmap of
mean log2 protein expression levels for each subpopulation of cells representing a distinct cell subtype. c)
Embedding of drug inhibitors, colored by clusters assigned by hierarchical clustering. d) Individual
inhibitors assigned to each inhibitor group. Histograms represent bin-wise mean of relative frequency of
each cell subtype for all inhibitors in a given group. The full list of inhibitors in each group can be found in
Table S5.

Note that in order to construct the cell-state manifold more efficiently, it was
beneficial to generate the reference cell-state embedding on a subsample of all cells
across all single-cell samples (and then to map unembedded cells to cell subtypes using a
nearest-neighbor approach). For the analysis of our EMT dataset, we chose to subsample
200 cells from each experimental condition. To assess whether this subsampling
procedure had adverse effects on recovering accurate sample-to-sample distances, we
first performed such a process on Synthetic Dataset A. We found that the sample-tosample distances were accurate (Pearson ρ > 99% between computed and ground-truth
distances) when subsampling 200 cells from each sample, even when the 200 cells
comprised as little as 1% of all cells in each sample. We then assessed whether the
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subsampling procedure introduced variability into the sample-to-sample distances
computed on our EMT dataset by comparing the correlation of results from 20 different
random subsamples applied to the same EMT dataset. We found that the correlation
between sample-to-sample distances across any two runs was greater than 98%.
Altogether, these results demonstrated that 200 cells were an adequate subsampling size
to yield stable results and that PhEMD was robust to different cell subsamplings.
Constructing and clustering the EMD-based drug-inhibitor manifold
After modeling the EMT cell-state space with PHATE, we used PhEMD to map the
experimental variable (i.e., single-cell specimen) state space as a low-dimensional
embedding. Specifically, EMD was computed pairwise between specimens based on cell
subpopulational differences among samples, and these specimen-to-specimen distances
(i.e., measures of dissimilarity) were used to generate a final low-dimensional diffusion
map in which specimens mapped closer to one another represented samples with more
similar cell subtype relative abundances (Figure 9C). The embedding of drug inhibitors
constructed as described above was then partitioned by applying hierarchical clustering to
the network of inhibitors. Note that the hierarchical clustering was performed on the
EMD-based sample-to-sample distance matrix prior to applying diffusion map
dimensionality reduction. Hierarchical clustering revealed clusters of inhibitors with
similar net effects on EMT; inhibitors assigned to the same cluster were assumed to have
similar effects on EMT. Moreover, by including “uninhibited” controls (samples in which
TGF-b1 was applied to induce EMT in absence of any inhibitor) and “untreated” controls
(samples in which neither TGF-b1 nor inhibitor was applied and no EMT was induced) in
our experiment, we were able to identify inhibitors with notable effects on EMT. Those
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inhibition conditions that clustered with uninhibited controls likely had little to no effect
on EMT, whereas those that clustered with untreated controls halted EMT strongly and
likely at an early stage.
The final embedding of drug inhibitors revealed a manifold structure that
highlighted the variable extent of EMT that had occurred in the different inhibition
conditions (Figure 9C-D). Partitioning the embedding into nine clusters (Clusters A-I,
Table S5), we found that Cluster A included the untreated controls and the TGFβ1receptor inhibitor condition, each of which consisted almost entirely of epithelial cells.
These were the experimental conditions in which EMT was actually or effectively not
induced. On the other hand, Cluster H included all five uninhibited control conditions and
inhibitors ineffective at modulating EMT; inhibitors in this cluster were found to have
mostly mesenchymal cells. Clusters B through G included inhibitors that had generally
decreasing strength with respect to halting EMT (Figure 9C-D). The EGFR and MEK1/2
inhibitors in Clusters B and C strongly inhibited EMT, as indicated by a marked
predominance of epithelial cells at time of CyTOF measurement. Cluster G mostly
consisted of Aurora kinase inhibitors and was characterized by a mixture of epithelial,
transitional, and mesenchymal cells with a relatively high proportion of C-4 cells
(consistent with the E+/M+ “hybrid” EMT phenotype).
The three inhibitors in Cluster I formed a small branch off the main EMT-extent
trajectory in the inhibitor embedding (Figure 9C). These three inhibitors targeted PI3K
and mTOR and each demonstrated a cell profile characterized by a relatively high
proportion of C-6 cells. Examining these results alongside measurements of cell yield in
each inhibition condition (Table S4), we attributed the relatively greater proportion of C-
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4 cells in the setting of Aurora kinase inhibition and of C-6 cells in the setting of
PI3K/mTOR inhibition to preferential drug-induced death of other cell types. C-4 and C6 cells were not uniquely generated by these inhibition conditions, as they were observed
in other samples including the uninhibited EMT control conditions (Figure 9C), but
appeared to have increased cell viability relative to other EMT cell types, especially in
the setting of targeted kinase inhibition (Table S4). Note that these findings were
consistent with those of the multi-batch experiment performed on batch-normalized data.
Altogether, consistent results were observed across all single-batch and multi-batch
analyses with respect to the resulting cell-state and higher-level biospecimen embeddings,
demonstrating PhEMD’s reproducibility and robustness to batch-normalized data (Figure
7, Figure 9–10).
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Figure 10. a) Cell subtype expression patterns and cell-state embeddings for three independent
experimental replicates. b) PhEMD biospecimen embeddings and inhibitor clusters for three independent
experimental replicates. The full list of inhibitors in each group can be found in Table S5.

Imputing the effects of inhibitors based on a small measured dictionary
In our model breast cancer system, we were able to use PhEMD to assess the effects of a
large panel of inhibitors on TGFβ1-induced EMT. We found that these inhibitors could be
grouped into clusters based on the similarity of their effects and embedded in low
dimension (with an intrinsic dimensionality of 2.4) to highlight complex, non-linear
relationships between samples. Visualizing this embedding of inhibition conditions in 3D,
we found that samples were distributed with varying density along a branched,
continuous manifold. For example, the embedding space containing Cluster H inhibitors
was characterized by high point density, while the embedding space containing Cluster B
points was more sparsely populated (Figure 7C). We also noted that clusters often
contained multiple inhibitors that targeted the same protein kinases. These findings
suggested that we may have been able to capture the geometry of the drug-inhibition state
space without measuring every single inhibition condition. If true, this finding would
have implications for potentially reducing the cost of conducting single-cell drug-screen
experiments, as it would suggest that only a small fraction of all inhibitors may need to
be experimentally tested using expensive single-cell profiling techniques to assess the
efficacy of a drug.
To test this hypothesis, we applied a previously published sampling technique to
our PhEMD embedding (65). The sampling technique used incompletely pivoted QR
decomposition to identify “landmark points” (inhibition or control conditions) that
approximately spanned the subspace of the single-cell sample embedding. Using this
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approach, we identified 34 landmark points that summarized our EMT perturbation state
space (Figure 11A). The 34 landmark points included samples from all 14 of Clusters AN, suggesting they spanned all classes of experimental conditions in our experiment. To
more fully assess whether the landmark points adequately captured the perturbation
landscape of our full 300-sample experiment, we applied an accompanying out-of-sample
extension technique to infer the embedding coordinates of all 300 samples relative to
these 34 landmark points. The resulting embedding had a similar geometry to that of our
original 300-sample PhEMD embedding, suggesting that the 34 landmark points were
sufficient to capture the overall network structure of all 300 measured experimental
conditions (Figure 7C, Figure 11B). Comparing the pairwise sample–sample distances of
all 300 samples in the 34-dimensional landmark-point space to the experimentally
computed EMD sample–sample distances, we found that there was strong correlation
between these distances (ρ=0.92). These findings supported the notion that redundancies
may exist in a drug screen experiment, and that one may not need to measure an
exhaustive set of perturbation conditions in order to infer the effects of all perturbations.
This highlights a potential opportunity for reducing the cost and improving the feasibility
of future single-cell drug-screen experiments. Based on our findings, only a small
fraction (11%) of all inhibitors may need to be experimentally measured using expensive
single-cell profiling techniques to learn the full spectrum of perturbation effects.
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Figure 11. a) Diffusion map embedding of 300-specimen EMT experiment, plotting only the 34 landmark
points identified using a previously published diffusion map sampling technique (see Methods). Points are
colored based on cluster assignments as determined based on original clustering of all 300 samples (see
Figure 7C). b) Reconstructed diffusion map embedding, generated by starting with the 34 landmark points
and using a previously published out-of-sample extension technique to infer the embedding coordinates of
all 300 samples relative to these 34 landmark points (see Methods).

Validating the PhEMD embedding using external information on similarities
between small-molecule inhibitors
We sought to validate our PhEMD drug-screen embedding by comparing the drug-drug
similarities learned from our experiment (in the context of effects on EMT) to drug-drug
similarities based on known drug-target binding specificities from a prior
experiment (66). Since the prior experiment and ours measured an overlapping set of
inhibitors, they could be conceptualized as two complementary “views” of the same
shared inhibitors. We hypothesized that for the inhibitors shared between the two
experiments, one view of the data might inform the other. Intuitively, this would support
the notion that drugs with more similar protein targets action may tend to have more
similar effects on EMT (and vice versa). Our approach to assessing this hypothesis was
twofold: 1) We used a measure of inhibitor–inhibitor similarity, derived from the drugtarget specificity data, to extend our PhEMD embedding and predict the effects of
unmeasured inhibitors on our model EMT system, and 2) We used our PhEMD
embedding to predict the drug-target specificity of inhibitors shared between the two
drug-screen experiments.
Predicting the effects of three selected inhibitors on breast cancer EMT relatively to the
effects of measured inhibitors based on known drug-target binding specificities
For the first task, we sought to evaluate whether we could leverage known information on
the mechanistic similarity between our inhibitors and additional inhibitors not measured
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in our experiment to predict the effects of these additional inhibitors on EMT. We
selected saracatinib, ibrutinib, and dasatinib as three nonspecific Src inhibitors whose
effects on EMT we wanted to predict. First, we generated a PhEMD embedding based on
our CyTOF experimental results (not including the three selected inhibitors). Then, we
obtained drug-target specificity data from a recently published inhibitor-profiling
experiment for inhibitors that overlapped between our experiment and the recently
published one (including the 3 Src inhibitors of interest). We used the drug-target
specificity data to compute pairwise cosine similarities between each of the 3 Src
inhibitors and the samples in our initial PhEMD diffusion map embedding (that did not
include the 3 inhibitors). These pairwise similarities were used to perform Nystrom
extension—a method of extending a diffusion map embedding to include new points
based on partial affinity to existing points (84–86). In this way, we were able to predict
the effects of the three Src inhibitors on breast cancer EMT relatively to inhibitors with
known, measured effects (Methods).
To validate our extended embedding containing predicted Src inhibitor effects, we
compared it to a “ground-truth” diffusion map embedding that used known (measured)
CyTOF expression data for the 3 inhibitors and explicitly included the 3 inhibitors along
with the rest in the initial embedding construction. Benchmarking our predictions against
this ground-truth model, we found that our predictive model mapped the three inhibitors
to the correct phenotypic space (Figure 12A-B). Specifically, saracatinib and ibrutinib
were predicted to have an effect intermediate to those of specific MEK and EGFR
inhibitors, and dasatinib was predicted to halt EMT less strongly than the other two Src
inhibitors. These findings are consistent with ground-truth results based on direct CyTOF
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profiling and PhEMD-modeling of the three inhibitors (Figure 12B; Methods).

Figure 12. a) Nystrom extension embedding showing predicted effect of 3 selected inhibitors (dasatinib,
ibrutinib, saracatinib) on EMT relatively to other measured inhibitors. b) PhEMD diffusion map embedding
showing measured effects of 3 selected inhibitors on EMT. c) Histogram showing distribution of prediction
error for null model (n=1000 independent permutations). Dotted red line represents prediction error for
actual prediction (i.e., alternative model). P-values were computed using a one-sided permutation test.

Imputing the single-cell phenotypes of three unmeasured inhibitors based on drug-target
similarity to measured inhibitors
We also hypothesized that we could use drug-target information to not only relate
unmeasured inhibitors to measured ones but also impute their single-cell compositions.
To test this, we used the Nystrom-extended PhEMD embedding as input into a partial
least squares regression model. We used this model to impute the cell subtype relative
frequencies for the three unmeasured (imputed) Src inhibitors (Methods). As validation,
we compared the predicted cell subtype relative frequencies to ground-truth CyTOF
results (i.e., actual single-cell measurements) for the three inhibitors. PhEMD accurately
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predicted the cell subtype relative frequencies for the three inhibitors compared to the
null model (P=0.01, P=0.01, P=0.03; Figure 12C).
To assess more generally whether PhEMD could be integrated with
complementary data to accurately predict perturbation effects, we performed leave-outout cross validation on all 39 inhibitors in our CyTOF experiment with known drug-target
specificity data (Methods). We found that single-cell profile predictions leveraging our
imputed PhEMD embedding were significantly more accurate than a null model
(P=0.005). Altogether, these findings suggested that PhEMD offered information that
could be integrated with additional data sources and data types to support not only
comparison of biospecimens directly measured but also prediction of single-cell
phenotypes for additional, unmeasured specimens.
Predicting drug-target binding specificities based on PhEMD results from EMT
perturbation experiment
We found that knowledge of drug-target binding specificity could be used to predict
inhibitor effects in our model EMT system. We then sought to assess whether the reverse
was true – whether the learned relationships between inhibitors from our EMT
perturbation experiment could be used to predict drug-target binding specificities. For
this prediction task, we used the 39 inhibitors that were present in both the drug-target
profiling experiment and ours, and that had at least 1 protein target identified by their
experiment. We then computed leave-one-out predictions using the MAGIC imputation
algorithm (67) and results from our EMT perturbation screen experiment to predict the
drug-target binding specificities of each inhibitor. Prediction accuracy was defined as the
correlation between predicted and measured drug-target binding specificities for a given
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drug. Our predictive model that incorporated PhEMD results into the prediction was
significantly more accurate than the null model (P=6.57x10-5; Figure 13). This suggested
that while the two experiments measured two distinct sets of inhibitor features, the
inhibitor–inhibitor relationships learned from both experiments were consistent.

Figure 13. a) Probability density functions representing distribution of Pearson correlations between
predicted and known drug-target binding specificity profiles. The null (n=39,000 predictions from 1,000
independent permutations) vs. alternative (n=39 predictions) models demonstrated median correlationbased accuracy of 0.02 vs. 0.25, P=8.2*10-6. Statistical testing was performed using a one-sided MannWhitney U-test. b) Pearson correlation-based prediction accuracy of null (n=1,000 permutations per
inhibitor) vs. alternative (one prediction per inhibitor) models for predicting the drug-target binding
specificity of each inhibitor. Given multiple null-model predictions for each inhibitor, the y-axis represents
mean prediction accuracy of all predictions for a given inhibitor. See Methods for detailed properties of the
null and alternative models.

PhEMD highlights manifold structure of tumor specimens measured using CyTOF
and single-cell RNA-sequencing
To demonstrate an additional application of the PhEMD analytical approach, we
used PhEMD to characterize the specimen-to-specimen heterogeneity in immune cell
profiles of multiple tumor specimens. We first applied PhEMD to a single-cell RNAsequencing dataset consisting of the “healthy” (non-malignant) cells of 17 melanoma
biopsies. The cell-state embedding identified a total of 10 cell subtypes with gene
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expression profiles consistent with previously reported subpopulations of B cells, T cells,
endothelial cells, epithelial cells, NK cells, and monocytes (Figure 14A-B) (12). Cell
subtypes C-1 and C-2 both represented CD8+ T cells. C-1 demonstrated high expression
of TIGIT, CTLA4, and LAG3 and was consistent with a T-cell exhaustion profile (87). C3 was comprised of CD4+ T cells. C-6 and C-7 represented CD19+ BLK+ B cells with
differences in the expression of SELL and CCR7. C-8 represented CD14+ monocytes
(88), C-9 represented PECAM1+ vWF+ CDH5+ endothelial cells, and C-10 represented
epithelial cells with high collagen expression.
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Figure 14. PhEMD applied to scRNA-sequencing data of 17 melanoma samples (non-tumor cells only)
highlights heterogeneous immune response amongst different patients. a) PHATE cell state embedding
colored by cell subtype. b) Heatmap showing mean RNA expression values of each cluster, colored by a
log2 scale. c) Diffusion map embedding of samples (colored by group assignment) revealing multiple
trajectories that represent increasing relative frequency of selected cell populations. d) Summary
histograms, each representing the bin-wise mean relative frequency of cell subtypes for all samples
assigned to a given group. The sample IDs (as assigned in the original dataset published by Tirosh et al.
(12)) of all samples in each inhibitor group can be found in Table S6.

When comparing and mapping patient specimens, PhEMD identified the
specimen ‘Mel75’ as having a unique immune cell profile characterized by the greatest
proportion of exhausted CD8+ T-cells. These cell-state and tumor-comparison findings
corroborated previously published results on the immune cell subtypes and inter-
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specimen heterogeneity present in this cohort (12). In addition to confirming prior
findings, this analysis yielded an embedding that revealed the manifold structure of the
single-cell specimen state space. With respect to a reference group of biospecimens
(Cluster D) that were comprised mostly of CD4+ T-cells and were mapped to one part of
the manifold, three axes of variation emerged that corresponded to increasing relative
proportions of B-cells (C-5, C-6), macrophages (C-7), and exhausted CD8+ T-cells (C-1)
(Figure 14C-D, Table S6). While it was well-understood that a set of individual cells,
such as those undergoing differentiation, may demonstrate manifold structure (56, 89),
our PhEMD embedding suggested that a set of patients with a shared phenotype (e.g.,
melanoma) may also lie on a continuous manifold (90).
To further explore this concept, we applied PhEMD to a mass cytometry dataset
containing the T-cell infiltrates of 75 clear cell renal cell carcinoma (ccRCC)
specimens (13). At the cellular level, our analysis recapitulated previous findings of
important T-cell subpopulations present (13). Cell subtype C-1 represented cells with
absent or low expression of both CD4 and CD8. C-2 through C-4 represented CD4+ Tcells with increasing expression of CD4, CD7, CCR7 and FOXP3, consistent with a
regulatory T-cell profile. C-5 represented CD4+ T-cells with high Ki-67, a well-known
proliferative marker. C-8 represented CD8+ cells with high expression of CD11b and
CD45RA.The trajectory from C-6 to C-7 to C-9 to C-10 represented CD8+ T-cells with
increasing expression of CD8, CD38, CD86, Ki-67, Tim-3, and PD-1. C-9 and C-10 cells
demonstrated the highest expression of the above markers, consistent with a T-cell
exhaustion profile (Figure 15A-B) (87).
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Figure 15. PhEMD applied to mass cytometry data of 75 ccRCC samples gated for T-cells. a) PHATE
embedding of T-cell manifold colored by cell subtype. b) Heatmap showing mean protein expression values
of each cell subtype cluster, colored by a log2 scale. c) Diffusion map embedding of all tumors colored by
tumor subgroup, defined by hierarchical clustering. The main axes of inter-sample variability are
highlighted as dotted-black trajectories. d) Summary histograms, each representing the bin-wise mean
relative frequency of cell subtypes for all samples assigned to a given group. The sample IDs (as assigned
in the original publication of these data (13)) of all samples in each inhibitor group can be found in Table
S7.

We then modeled the diversity in immune cell signatures as a tumor-specimen
embedding that could be used to characterize specimen-to-specimen variation (Figure
15C). A group of tumor specimens (Cluster B) mapping to one end of the PhEMD
embedding was characterized by a marked predominance of CD4+ T-cells (C-2, C-3), and
progression toward the other end of the tumor-space manifold represented a relative
decrease in CD4+ T-cells and marked relative increase in CD8+ PD1+ exhausted T-cells
(C-9, C-10) (Figure 15C, Table S7). This finding was supported by the initial report of
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substantial inter-patient variability in T-cell profiles especially related to CD8+ cells (13).
The detection of a subset of patients with exhausted T-cell enrichment may be of
particular clinical interest, as immunotherapy agents that combat T-cell exhaustion have
become a mainstay of advanced-stage ccRCC treatment, but patients continue to have
highly variable treatment responses (91, 92). Future single-cell tumor-profiling
experiments assessing treatment response may be able to use PhEMD as a tool to identify
subgroups of patients that might especially benefit from PD-1 or PD-L1 inhibitor
immunotherapy.

DISCUSSION
Here, we have demonstrated the successful mapping of single-cell experimental
conditions using our proposed PhEMD embedding technique. We extensively studied the
Py2T murine breast cancer cell line treated with TGF-b1 and perturbed with over 200
kinase inhibitors, measured using mass cytometry. In this experiment, PhEMD revealed
the structure of the kinase inhibitor space based on each drug’s effect on the Py2T cell
populations undergoing EMT. The final embedding of inhibitors was found to have lowdimensional structure, with drugs mapping to one of three main axes. We have shown
that the embedding produced by PhEMD is useful in several ways:
1. Visualizing the experimental variable (i.e., single-cell specimen) state space.
2. Identifying clusters of similar experimental variable settings (e.g., similar drugs
with respect to their measured effects on a given cell population).
3. Characterizing axes of variability among specimens in terms of biologically-
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interpretable differences in the types and abundances of cell subpopulations
present.
4. Extending the experimental variable state space through inference of unmeasured
experimental settings based on similarity to existing (measured) settings.
PhEMD can enable a new paradigm of searching for effective therapeutic agents by
identifying a small subset drugs that collectively capture the network geometry of a larger
drug set. We demonstrated this application by computing a dictionary of 34 experimental
conditions and showing that these experimental conditions were sufficient to capture the
network geometry of the 300-specimen state space. This finding has the potential to
reduce experimental burden in future drug discovery efforts. For example, one can first
apply PhEMD to measurements obtained using one profiling technique (e.g., mass
cytometry) to identify a small set of dictionary specimens from a large set of candidates
and then investigate this smaller set further using complementary technologies that may
be more limited in scale (e.g., single-cell RNA sequencing).
The PhEMD embedding can be integrated with additional data sources and data
types for even larger and richer analyses. By using drug-target specificity data from a
complementary inhibitor profiling experiment along with data imputation approaches, we
were able to accurately predict the effects of inhibitors not directly measured in our
experiment on TGFβ1-induced breast cancer EMT. This approach is useful for analyzing
drug-screen experiments, as it enables an initial mapping of a modest set of drugs (e.g.,
dictionary points) measured with single-cell resolution to be extended to include
additional drugs. This application is not limited to perturbation screen data and can be
useful for imputing the phenotypes of specimens (of any type) that are not directly
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measured using single-cell profiling. For example, examining a cohort of patients in
which only some patients were biopsied and genomically profiled, one could potentially
incorporate a non-genomic based measure of patient–to-patient similarity (e.g., based on
clinicopathologic features) to predict the single cell-based phenotypes of all patients in
the cohort.
We explored the applicability of PhEMD to other experimental designs besides
drug screens by applying it to single-cell data from two clinical tumor-biopsy cohorts.
These analyses revealed that PhEMD can uncover manifold structure in the tumorspecimen space that is biologically meaningful based on the observed proportions of the
specimens’ cell subpopulations. When applied to the melanoma and ccRCC datasets,
PhEMD revealed “trajectories” of patients, with the most notable axis in both datasets
consisting of patients with an increasing proportion of exhausted CD8+ T-cells. It is
possible that the abundance of tumor-infiltrating, exhausted T-cells may predict response
to immunotherapy, although additional studies are needed to assess this. The PhEMD
method may be useful for developing personalized cancer treatment regimens involving
immunotherapy.
This study is not without limitations. Our approach specifically compares cell
subtype relative abundances among biospecimens, which entails normalizing each
biospecimen by its total cell count. In this setting, since relative abundances by definition
sum to one for each biospecimen, the Earth Mover’s Distance is a true metric and is
robust across all pairwise comparisons of biospecimens. Comparing cell subtype relative
abundances rather than absolute abundances is also often preferable from a biological
perspective, as biospecimens (e.g., biopsy samples) may demonstrate variation in cell
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yield that is a technical artifact of little biological interest. Nevertheless, there exist
experimental scenarios in which cell yield is of biological importance. In future work, we
aim to incorporate cell yield into specimen-to-specimen comparisons and into the final
biospecimen embedding. Another area of active investigation is exploring alternative
methods of embedding the cell-subtype and biospecimen-state space. In the presented
experiments, PHATE was used to model the cell-subtype space and diffusion maps were
used to generate the biospecimen-state space. Future work may assess the utility of other
methods that are potentially applicable for these tasks.
In the present study, PhEMD was used to characterize mass cytometry and singlecell RNA-sequencing data, though PhEMD may be applied to data generated by other
single-cell profiling platforms as well. Many experimental designs may benefit from
PhEMD—for example, comparisons of specimens pre- and post-treatment (or receiving
different treatments), time-series analyses of cells undergoing transition processes, and
organization of heterogeneous-yet-related specimens for the purpose of disease
subtyping. Additionally, applying PhEMD to large-scale functional genomics (e.g.,
single-cell CRISPR) screens may yield embeddings that reveal complex relationships
between genes. We have demonstrated in our analysis of over 1.7 million cells across 300
specimens and five mass cytometry runs that PhEMD is highly scalable and robust to
batch effect. PhEMD offers the efficiency, flexibility, and model interpretability
necessary to analyze single-cell experiments of increasingly large scale and complexity.
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Table S1. List of inhibitors included in EMT drug-screen experiment.
Compound in DMSO

Cas Number

Reported Target

Axitinib

319460-85-0

VEGFR, PDGFR, c-Kit

Catalog
Number
S1005

Dovitinib (TKI-258)
Lapatinib Ditosylate
(Tykerb)
Sorafenib (Nexavar)

FLT3

S1018

A / B3

EGFR, HER2

S1028

A / B4

VEGFR, PDGFR, Raf

S1040

A / B5

EGFR, HER2

S1056

A / B6

SB 203580

405169-16-6, 804551-71-1
388082-77-7, 231277-92-2 (free base), 118753835-7 (4-methylbenzenesulfonate)
475207-59-1, 284461-73-0 (free base)
714971-09-2, 873837-23-1 (HCl), 873837-22-0
(H2O)
152121-47-6, 224047-03-4, 869185-85-3 (HCl)

p38 MAPK

S1076

A / B7

KU-55933

587871-26-9

ATM

S1092

A / B8

LY294002

154447-36-6, 934389-88-5 (HCl)
943540-75-8, 1093204-17-1 (X methanesulfonate),
1093204-20-6 (XHCl)

PI3K

S1105

A / B9

c-Met

S1114

A / B10

VEGFR

S1138

A / B11

Src, Bcr-Abl

S1006

A / C2

EGFR, HER2

S1019

A / C3

VEGFR, PDGFR, c-Kit

S1032

A / C4

BMS-599626 (AC480)

JNJ-38877605
Brivanib alaninate
(BMS-582664)

649735-63-7

Plate / Well
A / B2

CI-1033 (Canertinib)
Motesanib Diphosphate
(AMG-706)
Sunitinib Malate
(Sutent)
Masitinib (AB1010)

379231-04-6, 893428-72-3 (Fumaric acid),
893428-71-2 (3H2O)
267243-28-7, 289499-45-2 (2HCl)
857876-30-3, 453562-69-1 (free base), 945716-972 (H2O)
341031-54-7, 557795-19-4 (free base), 112664110-8 ( Maleic acid)
790299-79-5, 1048007-93-7 (methanesulfonate)

VEGFR, PDGFR, c-Kit, Flt

S1042

A / C5

c-Kit, PDGFR, FGFR, FAK

S1064

A / C6

SB 202190

152121-30-7, 350228-36-3 (HCl)

p38 MAPK

S1077

A / C7

GSK1904529A

1089283-49-7

IGF-1R

S1093

A / C8

OSU-03012
PD 0332991
(Palbociclib) HCl
AG-490

742112-33-0

PDK-1

S1106

A / C9

827022-32-2, 571190-30-2 (free base)

CDK

S1116

A / C10

133550-30-8

JAK, EGFR

S1143

A / C11

Saracatinib (AZD0530)

2

CI-1040 (PD184352)

606143-52-6, 942275-12-9 (4methylbenzenesulfonate)
212631-79-3

Nilotinib (AMN-107)

641571-10-0

Bcr-Abl

S1033

A / D4

Tandutinib (MLN518)

387867-13-2, 1227636-16-9 (3H2O)
957054-30-7, 957054-33-0 (dimethanesulfonate),
957054-54-5 (xTFA)
1032350-13-2, 1032349-93-1 (free base), 103234977-1 (HCl)
956905-27-4, 956906-93-7 (methanesulfonate),
1159490-81-9 (HCl)

Flt

S1043

A / D5

PI3K

S1065

A / D6

Akt

S1078

A / D7

c-Met

S1094

A / D8

827318-97-8

Aurora Kinase, FGFR, Bcr-Abl,
c-RET, Src

S1107

A / D9

35943-35-2

Akt

S1117

A / D10

345627-80-7, 345627-90-9 (HCl)

CDK

S1145

A / D11

656247-17-5, 790241-30-4 (methanesulfonate),
959761-73-0 (HCl)

VEGFR, PDGFR, FGFR

S1010

A / F2

572924-54-0, 697252-87-2

mTOR

S1022

A / F3

391210-10-9, 870474-62-7
443913-73-3, 338992-53-3 (TFA), 524722-52-9
(HCl)

MEK

S1036

A / F4

VEGFR

S1046

A / F5

877399-52-5, 877399-53-6 (acetate)

c-Met, ALK

S1068

A / F6

658084-23-2

c-Met

S1080

A / F7

212141-51-0, 212141-54-3 (free base)

VEGFR, c-Kit, Flt

S1101

A / F8

755038-02-9, 876126-71-5 (H2O)

PLK

S1109

A / F9

XL-184 (Cabozantinib)

849217-68-1,1140909-48-3 (L-(-)-Apple Acid)

VEGFR, c-Met, Flt, Tie-2, c-Kit

S1119

A / F10

PLX-4720

918505-84-7
439081-18-2, 936631-70-8 (Maleic acid),
1254955-21-9 (XHCl)

Raf

S1152

A / F11

EGFR, HER2

S1011

A / G2

AZD6244 (Selumetinib)

GDC-0941
MK-2206 2HCl
PF-04217903
Danusertib (PHA739358)
Triciribine (Triciribine
phosphate)
SNS-032 (BMS387032)
BIBF1120 (Vargatef)
Deforolimus
(Ridaforolimus)
PD0325901
Vandetanib (Zactima)
Crizotinib (PF02341066)
SU11274
Vatalanib 2HCl
(PTK787)
BI 2536

Afatinib (BIBW2992)

MEK

S1008

A / D2

MEK

S1020

A / D3

3
183319-69-9, 183321-74-6 (free base), 248594-196 (methanesulfonate)

EGFR

S1023

A / G3

639089-54-6, 639090-58-7 (sulfate)

Aurora Kinase

S1048

A / G5

477575-56-7, 1262750-60-6(HCl)

c-Met

S1070

A / G6

Brivanib (BMS-540215)

649735-46-6

VEGFR

S1084

A / G7

U0126-EtOH
Foretinib
(GSK1363089, XL880)
Everolimus (RAD001)
Roscovitine (Seliciclib,
CYC202)
CP-724714

1173097-76-1, 109511-58-2 (FREE BASE)

MEK

S1102

A / G8

849217-64-7, 1332889-22-1 (H2O)

c-Met, VEGFR

S1111

A / G9

159351-69-6, 1245613-55-1

mTOR

S1120

A / G10

186692-46-6

CDK

S1153

A / G11

537705-08-1

EGFR, HER2

S1167

B / B2

ENMD-2076

1291074-87-7

S1181

B / B3

Amuvatinib (MP-470)

850879-09-3

S1244

B / B4

AMG-208

1002304-34-8

Flt, Aurora Kinase, VEGFR
c-Met, c-Kit, PDGFR, Flt, cRET
c-Met

S1316

B / B5

AS-605240

648450-29-7

PI3K

S1410

B / B6

AS703026 (pimasertib)

1236699-92-5, 1236361-78-6 (HCl)

MEK

S1475

B / B7

CCT129202

942947-93-5

Aurora Kinase

S1519

B / B8

R406 (free base)

841290-80-0

Syk

S1533

B / B9

KU-60019

925701-49-1

ATM

S1570

B / B10

KW 2449

1000669-72-6

Flt, Bcr-Abl, Aurora Kinase

S2158

B / B11

TGX-221

663619-89-4

PI3K

S1169

B / C2

PIK-90

677338-12-4

677338-12-4

S1187

B / C3

JNJ-7706621

443797-96-4

CDK, Aurora Kinase

S1249

B / C4

TG100-115

677297-51-7, 677297-55-1 (2HCL)

PI3K

S1352

B / C5

Staurosporine

62996-74-1

PKC

S1421

B / C6

SB 525334

356559-20-1

TGF-beta/Smad

S1476

B / C7

Erlotinib HCl
VX-680 (MK-0457,
Tozasertib)
PHA-665752

4
XL765

PI3K, mTOR

S1523

B / C8

PDGFR

S1536

B / C9

BS-181 HCl

1349796-36-6, 1123889-87-1
343787-29-1, 343787-32-6 (4methylbenzenesulfonate)
1092443-52-1 (free base)

CDK

S1572

B / C10

WZ3146

1214265-56-1

EGFR

S1170

B / D2

PIK-75

372196-77-5, 372196-67-3 (free base)

PI3K, DNA-PK

S1205

B / D3

PD173074

219580-11-7

FGFR

S1264

B / D4

GSK1059615

958852-01-2, 1356195-42-0 (H2O . Na)

PI3K, mTOR

S1360

B / D5

Aurora A Inhibitor I

1158838-45-9

Aurora Kinase

S1451

B / D6

HMN-214

173529-46-9
844442-38-2, 902135-91-5 (HCl), 902135-89-1
(methanesulfonate)
1009298-09-2, 1201799-04-3 (D(-)-Tartaric Acid),
1201799-05-4 (Fumaric acid)

PLK

S1485

B / D7

CDK

S1524

B / D8

mTOR

S1555

B / D9

CP 673451

AT7519
AZD8055
BIRB 796
(Doramapimod)
LY2784544

285983-48-4, 1283526-53-3 (HCl)

p38 MAPK

S1574

B / D10

1229236-86-5, 1229236-87-6 (HCl)

JAK

S2179

B / D11

WZ4002

1213269-23-8

EGFR

S1173

B / F2

YM201636
Vemurafenib
(PLX4032)
ON-01910

371942-69-7, 371933-96-9 (2HCl)

PI3K

S1219

B / F3

918504-65-1

Raf

S1267

B / F4

1225497-78-8

PLK

S1362

B / F5

Thiazovivin

1226056-71-8, 1228446-06-7 (TFA)

ROCK

S1459

B / F6

PHA-793887

718630-59-2, 718630-60-5 (HCl)

CDK

S1487

B / F7

Hesperadin

422513-13-1

Aurora Kinase

S1529

B / F8

KRN 633

286370-15-8

VEGFR, PDGFR

S1557

B / F9

TWS119

601514-19-6

GSK-3

S1590

B / F10

AST-1306

1050500-29-2, 897383-62-9 (free base)

EGFR

S2185

B / F11

PD98059

167869-21-8

MEK

S1177

B / G2

5
OSI-930

728033-96-3

c-Kit, VEGFR

S1220

B / G3

IC-87114

371242-69-2

PI3K

S1268

B / G4

Ki8751

228559-41-9

VEGFR, c-Kit, PDGFR

S1363

B / G5

SP600125

129-56-6, 67072-00-8 (potassium salt)

JNK

S1460

B / G6

PIK-93

593960-11-3

PI3K, VEGFR

S1489

B / G7

BIX 02188

1094614-84-2

MEK

S1530

B / G8

AT7867

857531-00-1

Akt, S6 kinase

S1558

B / G9

BMS-265246

582315-72-8

CDK

S2014

B / G10

AZD8931

848942-61-0, 1196531-39-1 (diFumaric acid)

EGFR, HER2

S2192

B / G11

Raf265 derivative

927880-90-8

VEGFR, Raf

S2200

C / B2

PP242

1092351-67-1, 1173019-76-5 (H2O)

mTOR

S2218

C / B3

Palomid 529

914913-88-5

PI3K

S2238

C / B4

TAK-733

MEK

S2617

C / B5

Bcr-Abl

S2634

C / B6

AS-252424

1035555-63-5
1020172-07-9, 1020172-08-0 (2HCl), 1033893-296 (4-methylbenzenesulfonate)
900515-16-4

PI3K

S2671

C / B7

NVP-BSK805

1092499-93-8 (free base)

JAK

S2686

C / B8

AMG 900

945595-80-2

Aurora Kinase

S2719

C / B9

AZ628

878739-06-1

Raf

S2746

C / B11

BMS 794833

1174046-72-0, 1174161-83-1 (HCl)

c-Met, VEGFR

S2201

C / C2

Cyt387

1056634-68-4, 1056636-08-8 (XHCl)

JAK

S2219

C / C3

WP1130

856243-80-6

DUB, Bcr-Abl

S2243

C / C4

LDN193189

1062368-24-4, 1062368-62-0 (HCl)

TGF-beta/Smad

S2618

C / C5

CCT128930

Akt

S2635

C / C6

FAK

S2672

C / C7

WAY-600

885499-61-6
939791-38-5, 717907-75-0 (free base), 939791-396 (methanesulfonate)
1062159-35-6

mTOR

S2689

C / C8

ZM 336372

208260-29-1

Raf

S2720

C / C9

DCC-2036 (Rebastinib)

PF-00562271

6
TG101348
(SAR302503)
AMG458

936091-26-8, 1374744-69-0 (2ClH.H2O)

JAK

S2736

C / C10

913376-83-7

c-Met

S2747

C / C11

NVP-BHG712

940310-85-0

VEGFR, Src, Raf, Bcr-Abl

S2202

C / D2

SB590885
BKM120 (NVPBKM120)
AZD5438

405554-55-4
944396-07-0, 1312445-63-8 (HCl), 1370351-44-2
(0.5H2O)
602306-29-6

Raf

S2220

C / D3

PI3K

S2247

C / D4

CDK

S2621

C / D5

A66
GSK1120212
(Trametinib)
TG101209

1166227-08-2

PI3K

S2636

C / D6

871700-17-3, 871702-06-6 (sodium salt)

MEK

S2673

C / D7

936091-14-4

Flt, JAK, c-RET

S2692

C / D8

PF-03814735

942487-16-3

Aurora Kinase

S2725

C / D9

PKI-402

1173204-81-3, 1173204-82-4 (XHCl)

PI3K

S2739

C / D10

NVP-BGT226
R935788 (Fostamatinib
disodium, R788
disodium)
CAL-101 (GS-1101)

1245537-68-1, 915020-55-2 (free base)

PI3K

S2749

C / D11

1025687-58-4, 901119-35-5 (free base),118049089-4 (acetate)

Syk

S2206

C / F2

870281-82-6

PI3K

S2226

C / F3

Indirubin

479-41-4

GSK-3

S2386

C / F4

OSI-027

936890-98-1, 1187559-66-5 (sodium salt)

mTOR

S2624

C / F5

GSK2126458

1086062-66-9

PI3K, mTOR

S2658

C / F6

PCI-32765 (Ibrutinib)

936563-96-1

Src

S2680

C / F7

A-769662
Dacomitinib
(PF299804,PF00299804)
PHA-767491

844499-71-4

AMPK

S2697

C / F8

1110813-31-4, 1042385-75-0 (H2O)

EGFR

S2727

C / F9

845714-00-3, 942425-68-5 (HCl)

CDK

S2742

C / F10

Arry-380

937265-83-3

HER2

S2752

C / F11

PIK-293

900185-01-5

PI3K

S2207

C / G2

7
PIK-294

900185-02-6

PI3K

S2227

C / G3

Quercetin (Sophoretin)

117-39-5

PI3K, PKC, Src, Sirtuin

S2391

C / G4

R788 (Fostamatinib)

901119-35-5

Syk

S2625

C / G5

WYE-125132

1144068-46-1

mTOR

S2661

C / G6

AS-604850

648449-76-7
897016-82-9, 1038395-65-1 (2HCl), 1080645-95-9
(methanesulfonate), 1201926-60-4 (Maleic acid)

PI3K

S2681

C / G7

Src

S2700

C / G8

153436-53-4, 170449-18-0 (HCl)

EGFR

S2728

C / G9

1013101-36-4

mTOR, PI3K, Akt

S2743

C / G10

ARQ 197 (Tivantinib)

905854-02-6, 1000873-98-2, 1228508-24-4

c-Met

S2753

C / G11

NVP-BVU972

1185763-69-2

c-Met

S2761

D / B2

TAK-285

871026-44-7, 871027-78-0 (methanesulfonate)

EGFR

S2784

D / B3

GDC-0068
Desmethyl Erlotinib
(CP-473420)
TG 100713

1001264-89-6

Akt

S2808

D / B4

183321-86-0, 183320-51-6 (HCl)

EGFR

S2826

D / B5

925705-73-3

PI3K

S2870

D / B6

Wortmannin

19545-26-7, 1405-03-4

PI3K

S2758

D / B7

AZD2014
Dabrafenib
(GSK2118436)
TPCA-1

1009298-59-2
1195765-45-7, 1195768-06-9 (methanesulfonic
acid)
507475-17-4

mTOR

S2783

D / B8

Raf

S2807

D / B9

IKK

S2824

D / B10

WHI-P154

211555-04-3, 296234-84-9 (HCl)

JAK

S2867

D / B11

CH5424802

ALK

S2762

D / C2

c-Met

S2788

D / C3

INK 128 (MLN0128)

1256580-46-7, 1256589-74-8 (HCl)
1029712-80-8, 1029714-89-3 (XHCl), 119737685-4 (2HCl)
1224844-38-5

mTOR

S2811

D / C4

Torin 1

1222998-36-8

mTOR

S2827

D / C5

Piceatannol

10083-24-6, 21100-92-5

Syk

S3026

D / C6

KX2-391
AG-1478 (Tyrphostin
AG-1478)
PF-04691502

INCB28060

8
Dinaciclib
(SCH727965)

779353-01-4

CDK

S2768

D / C7

Sotrastaurin (AEB071)

425637-18-9, 1058706-32-3 (HCl), 1058706-35-6
(Maleic acid)

PKC

S2791

D / C8

148741-30-4

HER2

S2816

D / C9

194413-58-6

VEGFR

S2845

D / C10

VX-702

745833-23-2, 479543-46-9

p38 MAPK

S6005

D / C11

3-Methyladenine
Tofacitinib (CP-690550,
Tasocitinib)
BYL719

5142-23-4, 80681-18-1(HCl)

PI3K

S2767

D / D2

477600-75-2, 540737-29-9 (citrate)

JAK

S2789

D / D3

1217486-61-7

PI3K

S2814

D / D4

1433953-83-3

VEGFR

S2842

D / D5

540737-29-9, 477600-75-2 (free base)

JAK

S5001

D / D6

c-Met

S2774

D / D7

JAK

S2806

D / D8

Tyrphostin AG 879 (AG
879)
Semaxanib (SU5416)

SAR131675
Tofacitinib citrate (CP690550 citrate)

CEP33779

917879-39-1, 1196681-15-8, 1170702-87-0
(sodium salt)
1257704-57-6

Tideglusib

865854-05-3

GSK-3

S2823

D / D9

IMD 0354
Dovitinib Dilactic acid
(TKI258 Dilactic acid)
WP1066

978-62-1, 634914-41-3 (sodium salt )

IKK

S2864

D / D10

852433-84-2, 405169-16-6 (free base)

FLT3

S2769

D / F2

857064-38-1

JAK

S2796

D / F3

MK-2461

Torin 2
Baricitinib
(LY3009104,incb28050)
MK-5108 (VX-689)

1223001-51-1

mTOR

S2817

D / F4

1187594-09-7, 1187594-10-0 (TFA)

JAK

S2851

D / F5

1010085-13-8

Aurora Kinase

S2770

D / G2

AZD4547

1035270-39-3

FGFR

S2801

D / G3

NVP-TAE226

761437-28-9
928037-13-2 , 1007601-96-8 (L(+)-Tartaric Acid),
1007601-91-3 (Fumaric acid)
796967-16-3

FAK

S2820

D / G4

c-Met

S2859

D / G5

PDGFR, VEGFR

S1003

E / B2

Golvatinib (E7050)
Linifanib (ABT-869)

9
Cediranib (AZD2171)

288383-20-0

VEGFR, Flt

S1017

E / B3

Imatinib Mesylate

220127-57-1

PDGFR, c-Kit, Bcr-Abl

S1026

E / B4

Rapamycin (Sirolimus)

53123-88-9

mTOR

S1039

E / B5

Enzastaurin (LY317615)

170364-57-5

PKC

S1055

E / B6

SB 216763

280744-09-4

GSK-3

S1075

E / B7

Linsitinib (OSI-906)

867160-71-2

IGF-1R

S1091

E / B8

GDC-0879

905281-76-7

Raf

S1104

E / B9

GSK690693

937174-76-0

Akt

S1113

E / B10

AT9283
BEZ235 (NVPBEZ235)
Dasatinib (BMS354825)
Pazopanib HCl

896466-04-9

Bcr-Abl, JAK, Aurora Kinase

S1134

E / B11

915019-65-7

mTOR, PI3K

S1009

E / C2

302962-49-8

Src, Bcr-Abl, c-Kit

S1021

E / C3

635702-64-6

VEGFR, PDGFR, c-Kit

S1035

E / C4

Temsirolimus (Torisel)

162635-04-3

mTOR

S1044

E / C5

SB 431542

301836-41-9

TGF-beta/Smad

S1067

E / C6

PD153035 HCl

183322-45-4

EGFR

S1079

E / C7

MLN8054
TAE684 (NVPTAE684)
XL147
Barasertib (AZD1152HQPA)
Bosutinib (SKI-606)

869363-13-3

Aurora Kinase

S1100

E / C8

761439-42-3

ALK

S1108

E / C9

956958-53-5

PI3K

S1118

E / C10

722544-51-6

Aurora Kinase

S1147

E / C11

380843-75-4

Src

S1014

E / D2

Gefitinib (Iressa)

184475-35-2

EGFR

S1025

E / D3

PI-103

371935-74-9

DNA-PK, PI3K, mTOR

S1038

E / D4

Y-27632 2HCl

129830-38-2

ROCK

S1049

E / D5

ZSTK474

475110-96-4

PI3K

S1072

E / D6

NVP-ADW742

475488-23-4

IGF-1R

S1088

E / D7

10
ZM-447439

331771-20-1

Aurora Kinase

S1103

E / D8

SGX-523

1022150-57-7

c-Met

S1112

E / D9

MLN8237 (Alisertib)

1028486-01-2

Aurora Kinase

S1133

E / D10

SNS-314

1146618-41-8

Aurora Kinase

S1154

E / D11

E7080 (Lenvatinib)

417716-92-8

VEGFR

S1164

E / F2

WZ8040

1214265-57-2

EGFR

S1179

E / F3

AG-1024

65678-07-1

IGF-1R

S1234

E / F4

BX-912

702674-56-4

PDK-1

S1275

E / F5

Pelitinib (EKB-569)

257933-82-7

EGFR

S1392

E / F6

TSU-68

252916-29-3

VEGFR, PDGFR , FGFR

S1470

E / F7

LY2228820

862507-23-1

p38 MAPK

S1494

E / F8

AZD7762

860352-01-8

Chk

S1532

E / F9

PD318088

391210-00-7

MEK

S1568

E / F10

Neratinib (HKI-272)

698387-09-6

HER2, EGFR

S2150

E / F11

CYC116

693228-63-6

Aurora Kinase, VEGFR

S1171

E / G2

Tivozanib (AV-951)

475108-18-0

VEGFR, c-Kit, PDGFR

S1207

E / G3

WYE-354

1062169-56-5

mTOR

S1266

E / G4

MGCD-265

875337-44-3

c-Met, VEGFR, Tie-2

S1361

E / G5

PHA-680632
AEE788 (NVPAEE788)
Quizartinib (AC220)

398493-79-3

Aurora Kinase

S1454

E / G6

497839-62-0

EGFR, Flt, VEGFR, HER2

S1486

E / G7

950769-58-1

Flt

S1526

E / G8

PHT-427

1191951-57-1

Akt

S1556

E / G9

Tie2 kinase inhibitor

948557-43-5

Tie-2

S1577

E / G10

BGJ398 (NVP-BGJ398)

872511-34-7

FGFR

S2183

E / G11

1
Table S2. List of antibodies included in EMT drug-screen experiment.
Isotope

Target

Clone

Clone
Reactivity

Clone
Applications

Manufacturer

Lot

Description and Clone Validation
(Manufacturer)

Staining
Concentrati
on [µg/ml]

User Clone Validation
(Py2T by Mass
Cytometry)

La139

Purified
Mouse
Anti-CREB
(pS133) /
ATF-1
(pS63)
pStat5
(pTyr694)

J15121

Human,
Mouse, Rat
(predicted)

WB, FC

BD

558359

https://www.bdbiosciences.com/us/reagents/r
esearch/antibodies-buffers/cell-biologyreagents/cell-biology-antibodies/purifiedmouse-anti-creb-ps133-atf-1-ps63-j15121/p/558359

2

Py2T, MEK1/2 signaling
perturbation

47

Mouse;
Human

WB, FC

BD

2150654

4.9

30 min vanadate treatment,
125µM vs 30 min
Untreated

Nd142

pSHP2
(pTyr580)

D66F1
0

Human;
Mouse; Rat

WB, IP, FC

CST

2

4

18 h TPA vs Untreated

Nd143

pFAK
(pTyr397)

poly7

Human;
Mouse

WB

CST

5

2.5

5 Days 4 ng/mL TGFb vs
5 Days Untreated

Nd144

MEK1/2
(pSer221)

166F8

Human;
Mouse

WB, IHC,
FC

CST

13

https://www.bdbiosciences.com/us/applicatio
ns/research/stem-cell-research/stem-cellsignaling/human/purified-mouse-anti-humanstat5-py694-47stat5py694/p/611965
https://www.cellsignal.com/products/primary
-antibodies/phospho-shp-2-tyr580-d66f10rabbit-mab/5431
https://www.cellsignal.com/products/primary
-antibodies/phospho-fak-tyr397antibody/3283?site-search-type=Products
https://www.cellsignal.com/products/primary
-antibodies/phospho-mek1-2-ser221-166f8rabbit-mab/2338?site-search-type=Products

4

Nd145

Twist

poly
ABD29

Mouse;
Human

IH(P), ICC

Millipore

ABD29

4

Nd147

c-myc

D84C1
2

Human;
Mouse

WB, IF, FC

CST

7

Nd148

Snail

ab1807
14

Human;
Mouse

Abcam

AF3639

Nd149

Nanog

D2A3

Mouse

IHC-Fr, WB,
ICC/IF, IHCP
WB, IP, FC,
IF, ChiP

http://www.merckmillipore.com/NL/en/prod
uct/Anti-Twist1-Twist-related-protein-1Antibody,MM_NFABD29?ReferrerURL=https%3A%2F%2Fw
ww.google.com%2F&bd=1
https://www.cellsignal.com/products/primary
-antibodies/c-myc-d84c12-rabbitmab/5605?site-search-type=Products
https://www.abcam.com/snail-slug-antibodyab180714.html

30 min 4 ng/mL TGFb +
Dabrafenib, AZ628 (bRaf,
cRaf inhibitors) vs 30 min
4 ng/mL TGFb
3 Days 4 ng/mL TGFb vs
3 Days Untreated

BD

2

https://www.cellsignal.com/products/primary
-antibodies/nanog-d2a3-xp-rabbit-mabmouse-specific/8822

Pr141

Nd150
NFkB
(p65)

Polyclo
nal

Human,
Mouse

FC, ChIP,
ICC,
ChIP/Chip,
EMSA, IP,
IHC-P, WB,

6

18 h TPA vs Untreated

5

3 Days 4 ng/mL TGFb vs
3 Days Untreated

3

Not validated by user
Not validated by user

Abcam

NA

https://www.abcam.com/NF-kB-p65antibody-ChIP-Grade-ab7970.html

3

2
IHC-Fr,
ICC/IF
FC, WB

BD

2150665

Eu151

pP38
(pThr180/p
Tyr182)

36/p38

Human;
Mouse

Sm152

pAMPK
(pThr172)

40H9

WB, IP, ICH

CST

18

Eu153

pAkt
(pSer473)

D9E

Human;
Mouse;
Rat....
Human;
Mouse;
Rat....

WB, IP,
IHC, IF, FC

CST

20

Sm154

pErk1/2
(pThr202/p
Tyr204)

20A

Human;
Mouse

FC, WB

BD

2153932

Gd156

CyclinB1

GNS11

Human;
Mouse

WB, IP, FC

BD

4241979

Gd158

pGSK3
(pSer9)

D85E1
2

Human;
Mouse

WB, IP, IF,
FC

CST

5558BF

Tb159

41D10

Human;
Mouse

WB, IF, FC

CST

9516BF

Gd160

pSmad1/5
(pSer463/S
er465)
CD44

IM7

Human;
Mouse

FC

BD

550538

Dy162

Vimentin

D21H3

Human;
Mouse

WB, ICH,
IF, FC

CST

5741BF

Dy164

pSmad2/3
(pSmad2(p
Ser465/Ser
467)/pSma
d3(pSer423
/Ser425)
ß-Catenin

D27F4

Human;
Mouse

WB

CST

5

D13A1

Human;
Mouse

WB, IP,
IHC, IF, FC,
ChIP

CST

8814BF

Ho165

https://www.bdbiosciences.com/eu/applicatio
ns/research/b-cell-research/intracellularantigens/human/pe-mouse-anti-p38-mapkpt180py182-36p38-pt180py182/p/612565
https://www.cellsignal.com/products/primary
-antibodies/phospho-ampka-thr172-40h9rabbit-mab/2535
https://www.cellsignal.com/products/primary
-antibodies/phospho-akt-ser473-d9e-xprabbit-mab/4060

4

30 min vanadate treatment,
125µM vs 30 min
Untreated

4

https://www.bdbiosciences.com/us/applicatio
ns/research/intracellular-flow/intracellularantibodies-and-isotype-controls/anti-ratantibodies/pe-mouse-anti-erk12-pt202py20420a/p/561991
https://www.bdbiosciences.com/us/applicatio
ns/research/apoptosis/purifiedantibodies/purified-mouse-anti-cyclin-b1gns-11/p/554179
https://www.cellsignal.com/products/primary
-antibodies/phospho-gsk-3b-ser9-d85e12-xprabbit-mab/5558
https://www.cellsignal.com/products/primary
-antibodies/phospho-smad1-5-ser463-46541d10-rabbit-mab/9516
https://www.bdbiosciences.com/eu/applicatio
ns/research/t-cell-immunology/t-follicularhelper-tfh-cells/surfacemarkers/mouse/purified-rat-anti-mouse-cd44im7/p/550538
https://www.cellsignal.com/products/primary
-antibodies/vimentin-d21h3-xp-rabbitmab/5741
https://www.cellsignal.com/products/primary
-antibodies/phospho-smad2-ser465-467smad3-ser423-425-d27f4-rabbit-mab/8828

2

30 min vanadate treatment,
125µM vs 30 min
Untreated
30 min 4 ng/mL TGFb +
GDC09411 (PI3K
inhibitor) vs 30 min 4
ng/mL TGFb
30 min 4 ng/mL TGFb +
PD325901 (MEK1/2
inhibitor) vs 30 min 4
ng/mL TGFb

https://www.cellsignal.com/products/primary
-antibodies/non-phospho-active-b-cateninser33-37-thr41-d13a1-rabbit-mab/8814

5

8

Cyclin B1 vs IdU

1

30 min 4 ng/mL TGFb +
MK2260 (AKT inhibitor)
vs 30 min 4 ng/mL TGFb
Not validated by user

6
0.085

3 Days 4 ng/mL TGFb vs
3 Days Untreated

1

3 Days 4 ng/mL TGFb vs
3 Days Untreated

2

30 min 4 ng/mL TGFb +
SB431542 (TGFßR
inhibitor) vs 30 min 4
ng/mL TGFb

2

3 Days 4 ng/mL TGFb vs
3 Days Untreated

3
Er167

pMARCK
(pSer167/S
er170)
CD24

D13E4

Human;
Mouse; Rat

WB, IF, FC

CST

3

30-F1

Mouse

FC

Biolegend

138502

Tm169

pPLC
gamma-2
(pTyr759)

K86689.37

Human;
Mouse

FC

BD

2150657

Er170

pHistone
H3
(pSer28)

HTA28

Human;
Mouse

Biolegend

641002

Yb171

pS6
p(pSer235/
Ser236)

N7-548

Human;
Mouse

WB,
CyTOF,
ICC, IP,
ICFC
FC

BD

2150655

Yb172

Cleaved
Caspase 3

C92605

Human;
Mouse

FC, WB, IP

CST

559565

Yb173

pSTAT3
(pThr727)

49/pST
AT3

Human;
Mouse

FC, IF, WB

BD

2150654

Yb174

E-Cadherin

36/ECadh

Human;
Mouse

WB, IP, IF,
IHC

BD

610182

Lu175

pRb
(pSer807/8
11)
Survivin

D20B1
2

Human;
Mouse;
Rat....
Human;
Mouse; Rat

WB, IP, IF,
IHC, FC

CST

5

WB, IP,
IHC, IF, FC

CST

14

Er168

Yb176

71G4B
7

https://www.cellsignal.com/products/primary
-antibodies/phospho-marcks-ser167-170d13e4-xp-rabbit-mab/8722
https://www.biolegend.com/enus/products/purified-anti-mouse-cd24antibody-6616
https://www.bdbiosciences.com/us/applicatio
ns/research/intracellular-flow/intracellularantibodies-and-isotype-controls/anti-humanantibodies/pe-mouse-anti-plc-2-py759-k8668937/p/558490
https://www.biolegend.com/deat/products/purified-anti-histone-h3phosphorylated-ser28-antibody-5169
https://www.bdbiosciences.com/eu/applicatio
ns/research/intracellular-flow/intracellularantibodies-and-isotype-controls/anti-humanantibodies/pe-mouse-anti-s6-ps235ps236-n7548/p/560433
https://www.bdbiosciences.com/us/applicatio
ns/research/intracellular-flow/intracellularantibodies-and-isotype-controls/anti-humanantibodies/purified-rabbit-anti--activecaspase-3-c92-605/p/559565
https://www.bdbiosciences.com/eu/applicatio
ns/research/t-cell-immunology/th17cells/intracellular-markers/cell-signallingand-transcription-factors/human/purifiedmouse-anti-stat3-ps727-49p-stat3/p/612542 ,
https://www.bdbiosciences.com/eu/applicatio
ns/re
https://www.bdbiosciences.com/eu/applicatio
ns/research/stem-cell-research/cancerresearch/human/purified-mouse-anti-ecadherin-36e-cadherin/p/610181
https://www.cellsignal.com/products/primary
-antibodies/phospho-rb-ser807-811-d20b12xp-rabbit-mab/8516
https://www.cellsignal.com/products/primary
-antibodies/survivin-71g4b7-rabbitmab/2808?site-search-type=Products

7

Not validated by user

3

3 Days 4 ng/mL TGFb vs
3 Days Untreated

5

30 min 4 ng/mL TGFb +
PP121 (PDGFR inhibitor)
vs 30 min 4ng/mL TGFß

1.5

Untreated Py2T IdU vs
pH3

2

30 min 4ng/ mL TGFb + 1
µM PD325901 vs 30 min
4ng/ mL TGFb

5

5 Days Dinaciclib (1µM) +
4ng/mL TGFß vs 5 Days
4ng/mL TGFß

6

Not validated by user

1

11 Days Untreated Py2T
vs 11 Days 4ng/mL TGF-ß

4.5

Untreated Py2T IdU vs
CyclinB

4

BIRC5 overexpression

1
Table S3. Clusters of inhibitors with similar effects in multiple-batch EMT drug-screen experiment.
Cluster A

Cluster B

TAK-733 (MEK12)

Ibrutinib (Src)

Untreated control

Trametinib (MEK12)

Untreated control
Untreated control

Canertinib (EGFR)
PD0325901
(MEK1:2)

Untreated control

SB525334 (TGFbR1)

Untreated control

SB431542 (TGFR)

Saracatinib (Src)
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control
AS703026
(MEK12)
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control
Untreated control

Cluster C
Dacomitinib
(EGFR)
GSK2126458
(PI3K)
Erlotinib
(EGFR)
Vargatef
(VEGFR)
AST-1306
(EGFR)
AZD8931
(EGFR)
CP-473420
(EGFR)
WHI-P154
(JAK3)
AEE788
(EGFR)
Gefitinib
(EGFR)

Cluster D
LDN193189 (TGFbeta:Smad)

Cluster E

Cluster F

Cluster G

Cluster H

AZD5438 (CDK)

AMG 900 (Aurora Kinase)

Cyt387 (JAK12)

Afatinib (EGFR)

AZ628 (Raf)
Amuvatinib
(cMet)

NVP-BGT226 (PI3K)

Indirubin (GSK-3b)

CI-1040 (MEK1:2)

Torin1 (mTOR)

Foretinib (c-Met)
Tozasertib (Aurora
Kinase)

NVP-BHG712 (VEGFR)

Selumetinib (MEK1:2)

AZD7762 (Chk)

SP600125 (JNK12)

PF-00562271 (FAK)
PF-03814735 (Aurora
KinaseAB)

KW 2449 (Flt)

BEZ235 (mTOR)

Bosutinib (Bcr-Abl)

TG101209 (Flt)

Rebastinib (Bcr-Abl)

WZ3146 (EGFR)

Dasatinib (Src)

Pelitinib (EGFR)

BI 2536 (PLK1)

Deforolimus (mTOR)

IMD 0354 (IKKa)

AT9283 (AuroraK)

Sunitinib (VEGFR)

PD153035 (EGFR)

Barasertib (AuroraK)

Vandetanib (VEGFR)

PD318088 (MEK12)

CYC116 (AuroraK)

AT7867 (Akt)

WZ8040 (EGFR)

MLN8054 (AuroraK-A)
MLN8237 (AuroraK-A)
Neratinib (HER2)

CP 673451 (PDGFRb)
Ki8751 (VEGFR)
R406 (Syk)

Pazopanib (VEGFR1)
SNS314 (AuroraK-A)
TAE684 (ALK)

Thiazovivin (ROCK)
XL765 (PI3K)
YM201636 (PI3K)
CEP33779 (JAK2)
CH5424802 (ALK)
Dovitinib (FLT3)
Semaxanib (VEGFR)
Linifanib (PDGFRb)
LY2228820
(p38MAPKa)
Rapamycin (mTOR)
Temsirolimus (mTOR)
Tie2Kinhibitor (Tie2)

R935788 (Syk)
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Cluster I
A-769662 (AMPK)
A66 (PI3K)
AMG458 (c-Met)
Arry-380 (HER2)
AS-252424 (PI3K)
AS-604850 (PI3K)
TGFb-only control
BMS 794833 (c-Met)
CAL-101 (PI3K)
CCT128930 (Akt)
TGFb-only control
TGFb-only control
TGFb-only control
TGFb-only control
TGFb-only control
Fostamatinib (Syk)
KX2-391 (Src)
NVP-BSK805 (JAK12)
Palomid 529 (PI3K)
PF-04691502 (mTOR)
PHA-767491 (Cdc7:CDK9)
PIK-293 (PI3K)
PIK-294 (PI3K)
Quercetin (PI3K)
Raf265 (VEGFR)
SB590885 (bRaf)
TG101348 (JAK2)
Tivantinib (c-Met)
Tyrphostin (EGFR)
WP1130 (DUB)
WYE-125132 (mTOR)
ZM 336372 (cRaf)
AG-490 (JAK)
Axitinib (VEGFR)
…

Cluster J
BMS-599626 (EGFR)
Lapatinib (EGFR)
AZD8055 (mTOR)
HMN-214 (PLK1)
ON-01910 (PLK1)
PHA-793887 (CDK)
Dabrafenib (b-Raf)
TAK-285 (EGFR)

Cluster K
BKM120 (PI3K)
OSI-027 (mTOR)
PKI-402 (PI3K)
PP242 (mTOR)
WAY-600 (mTOR)
GDC-0941 (PI3K)
MK-2206 (Akt123)
GSK1059615 (PI3K)
PIK-90 (PI3K)
AZD2014 (mTOR)
BYL719 (PI3K)
INK128 (mTOR)
PI-103 (PI3K, DNA-PK)
WYE354 (mTOR)
ZSTK474 (PI3K)

Cluster L
Hesperadin (AuroraKinaseB)
Dinaciclib (CDK2)

Cluster M
PIK-75 (PI3K)

Cluster N
Torin2 (mTOR)
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Table S4. Cell yield of each experimental condition in EMT drug-screen experiment
Dinaciclib (CDK2)
PIK-75 (PI3K)
SP600125 (JNK12)
Tozasertib (Aurora Kinase)
BI 2536 (PLK1)
Hesperadin (AuroraKinaseB)
HMN-214 (PLK1)
IMD 0354 (IKKa)
ON-01910 (PLK1)
Foretinib (c-Met)
Torin2 (mTOR)
WZ3146 (EGFR)
KW 2449 (Flt)
AZD8055 (mTOR)
Canertinib (EGFR)
CYC116 (AuroraK)
PIK-90 (PI3K)
Afatinib (EGFR)
GSK2126458 (PI3K)
PD0325901 (MEK1:2)
GSK1059615 (PI3K)
Torin1 (mTOR)
SNS314 (AuroraK-A)
GDC-0941 (PI3K)
Triciribine (Akt)
PHA-793887 (CDK)
Amuvatinib (cMet)
AT9283 (Bcr-Abl)
MLN8237 (AuroraK-A)
Erlotinib (EGFR)
Everolimus (mTOR)
BEZ235 (mTOR)
AS703026 (MEK12)
MK-2206 (Akt123)
Barasertib (AuroraK)
Axitinib (VEGFR)
AMG 900 (Aurora Kinase)
ENMD-2076 (Flt)
AuroraA (inhibitor)
AZD2014 (mTOR)
AST-1306 (EGFR)
INK128 (mTOR)
AZD8931 (EGFR)
BMS-265246 (CDK1:cyclinB)

42
54
82
98
129
145
237
257
288
294
298
384
494
581
617
630
631
743
755
803
808
826
853
909
914
946
977
1000
1010
1025
1028
1074
1086
1087
1133
1155
1199
1210
1263
1277
1318
1328
1339
1347
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Saracatinib (Src)
Deforolimus (mTOR)
PF-03814735 (Aurora KinaseAB)
BS-181 (CDK)
Untreated control
AZD7762 (Chk)
Vandetanib (VEGFR)
SB525334 (TGFbR1)
JNJ-7706621 (CDK1:CyclinB)
XL765 (PI3K)
CCT129202 (AuroraKinaseABC)
PD173074 (FGFR1)
Untreated control
Untreated control
Pelitinib (EGFR)
Vargatef (VEGFR)
CP-473420 (EGFR)
Crizotinib (c-Met)
AT7867 (Akt)
BYL719 (PI3K)
Untreated control
AMG-208 (c-Met)
NVP-BGT226 (PI3K)
LY2784544 (JAK2)
WZ4002 (EGFR)
CI-1040 (MEK1:2)
Untreated control
AT7519 (CDK1:cyclinB)
Untreated control
TGX-221 (PI3K)
Selumetinib (MEK1:2)
Lapatinib (EGFR)
BMS-599626 (EGFR)
Untreated control
Neratinib (HER2)
TWS119 (GSK3b)
KU-60019 (ATM)
KRN 633 (VEGFR)
CP-724714 (EGFR)
PD98059 (MEK12)
OSI-930 (cKit)
U0126 (MEK1:2)
Ki8751 (VEGFR)
IC-87114 (PI3K)
Palbociclib (CDK4:6)

1409
1417
1438
1445
1457
1592
1598
1650
1711
1742
1751
1789
1834
1907
1908
1926
1939
1947
1985
2011
2032
2047
2059
2080
2117
2141
2152
2156
2158
2180
2205
2210
2211
2219
2250
2259
2330
2335
2359
2363
2376
2409
2422
2445
2484
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SNS-032 (CDK2:7:9)
BIRB 796 (p38MAPK)
Dasatinib (Src)
TG100-115 (PI3K)
YM201636 (PI3K)
PIK-93 (PI3K)
Motesanib (VEGFR)
Staurosporine (PKC)
BIX 02188 (MEK5)
Untreated control
Danusertib (Aurora Kinase)
PHA-665752 (c-Met)
KU-55933 (ATM)
Untreated control
SU11274 (c-Met)
LY294002 (PI3K)
Sunitinib (VEGFR)
TGFb-only control
Untreated control
Dovitinib (FLT3)
AZD5438 (CDK)
TGFb-only control
AS-605240 (PI3K)
TGFb-only control
R406 (Syk)
SB 203580 (p38 MAPK)
Masitinib (c-Kit)
Vemurafenib (bRAF)
TGFb-only control
TGFb-only control
Brivanib (VEGFR)
CP 673451 (PDGFRb)
OSU-03012 (PDK-1)
Vatalanib (VEGFR)
Sorafenib (VEGFR)
Roscovitine (CDK)
Tandutinib (Flt3)
TGFb-only control
PD153035 (EGFR)
ZSTK474 (PI3K)
Trametinib (MEK12)
Untreated control
Cabozantinib ( VEGFR2)
Nilotinib (Bcr-Abl)
Untreated control

2503
2509
2510
2521
2543
2559
2592
2612
2622
2625
2644
2695
2725
2731
2761
2771
2785
2788
2845
2866
2888
2909
2930
2930
2942
2972
2977
2996
3001
3006
3014
3036
3053
3055
3075
3080
3080
3082
3085
3104
3126
3146
3187
3223
3269

4
TGFb-only control
MLN8054 (AuroraK-A)
AEE788 (EGFR)
WHI-P154 (JAK3)
PLX-4720 (bRAF)
SB 202190 (p38 MAPK)
PI-103 (DNA-PK)
Untreated control
Thiazovivin (ROCK)
AG-490 (JAK)
PP242 (5Days)
PF-04217903 (c-Met)
Brivanib (VEGFR)
JNJ-38877605 (c-Met)
Untreated control
TGFb-only control
WYE354 (mTOR)
Temsirolimus (mTOR)
Pazopanib (VEGFR1)
PD318088 (MEK12)
TAE684 (ALK)
Wortmannin (PI3K)
GSK1904529A (IGF-1R)
TAK-285 (EGFR)
TGFb-only control
SB431542 (TGFR)
TG101209 (Flt)
TGFb-only control
NVP-BVU972 (c-Met)
CH5424802 (ALK)
TGFb-only control
TAK-733 (MEK12)
Untreated control
TGFb-only control
Rapamycin (mTOR)
TPCA-1 (IKK2)
TG100713 (PI3K)
GDC-0068 (Akt123)
SAR131675 (VEGFR)
WP1066 (JAK2)
PKI-402 (PI3K)
BKM120 (PI3K)
Dabrafenib (b)
WZ8040 (EGFR)
Untreated control

3282
3290
3297
3330
3343
3361
3383
3425
3441
3465
3477
3505
3563
3622
3656
3668
3672
3698
3763
3812
3875
3902
3906
3918
3948
4021
4046
4052
4096
4126
4272
4280
4287
4321
4379
4464
4561
4635
4940
4973
5139
5148
5279
5283
5294
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LY2228820 (p38MAPKa)
NVP-ADW742 (IGF-1R)
Dovitinib (FLT3)
Gefitinib (EGFR)
TGFb-only control
Semaxanib (VEGFR)
TGFb-only control
TGFb-only control
MK-5108 (Aurora KinaseA)
TGFb-only control
Untreated control
AZD4547 (FGFR)
Tyrphostin (HER2)
Piceatannol (Syk)
TGFb-only control
NVP-TAE226 (FAK)
Untreated control
TGFb-only control
3-Methyladenine (PI3K)
Golvatinib (c-Met)
TGFb-only control
TGFb-only control
MK-2461 (c-Met)
Untreated control
Bosutinib (Src)
TGFb-only control
Tofacitinib (citrate)
INCB28060 (c-Met)
TGFb-only control
TGFb-only control
TGFb-only control
Tofacitinib (JAK3)
Dacomitinib (EGFR)
TGFb-only control
Tideglusib (GSK-3)
Sotrastaurin (PKC)
TGFb-only control
Untreated control
TGFb-only control
TGFb-only control
Baricitinib (JAK1)
Quizartinib (Flt3)
Ibrutinib (Src)
VX-702 (p38 MAPK)
MGCD-265 ( c-MET)

5340
5371
5387
5393
5456
5487
5595
5596
5609
5624
5711
5713
5714
5827
5832
5860
5874
5902
5947
5966
6028
6101
6113
6174
6247
6262
6392
6412
6445
6454
6515
6555
6561
6633
6677
6685
6688
6695
6789
6793
6864
6942
7074
7140
7228
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TGFb-only control
Cediranib (VEGFR)
Linsitinib (IGF-1R)
TGFb-only control
TGFb-only control
TGFb-only control
E7080 (VEGFR2)
TGFb-only control
OSI-027 (F5.csv)
CEP33779 (JAK2)
PHA680632 (AuroraK)
TGFb-only control
Tivozanib (VEGFR1)
Linifanib (PDGFRb)
BX912 (PDK-1)
GSK690693 (Akt1)
GDC0879 (B-Raf)
WAY-600 (mTOR)
ZM-447439 (AuroraK-A)
TGFb-only control
Enzastaurin (PKC)
PF-00562271 (FAK)
AG1024 (IGF-1R)
PHT427 (Akt)
Imatinib (PDGFR)
BGJ398 (FGFR1)
TSU68 (VEGFR1)
XL147 (PI3K)
Y-27632 (p160ROCK)
Tie2Kinhibitor (Tie2)
SGX523 (HGFR)
AS-604850 (PI3K)
A66 (PI3K)
PIK-293 (PI3K)
AZ628 (Raf)
SB216763 (GSK-3a)
TGFb-only control
PIK-294 (PI3K)
CAL-101 (PI3K)
Palomid 529 (PI3K)
R935788 (Syk)
WYE-125132 (mTOR)
LDN193189 (TGF-beta:Smad)
TGFb-only control
Tyrphostin (EGFR)

7335
7378
7397
7443
7610
7667
7722
8071
8209
8214
8257
8275
8297
8455
8462
8986
9309
9364
9415
9670
9894
9920
10343
10497
10597
10677
10677
11193
11615
11676
12691
12762
12871
14011
14111
14224
14558
14641
14686
14718
14770
14920
15493
15640
15705
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PF-04691502 (mTOR)
AMG458 (c-Met)
Untreated control
Fostamatinib (Syk)
Tivantinib (c-Met)
KX2-391 (Src)
Arry-380 (HER2)
BMS 794833 (c-Met)
A-769662 (AMPK)
TGFb-only control
Untreated control
Quercetin (PI3K)
ZM 336372 (cRaf)
TGFb-only control
TG101348 (JAK2)
NVP-BSK805 (JAK12)
Untreated control
Indirubin (GSK-3b)
Untreated control
Untreated control
WP1130 (DUB)
Raf265 (VEGFR)
SB590885 (bRaf)
TGFb-only control
TGFb-only control
NVP-BHG712 (VEGFR)
AS-252424 (PI3K)
CCT128930 (Akt)
Cyt387 (JAK12)
PHA-767491 (Cdc7:CDK9)
Rebastinib (Bcr-Abl)

15787
15862
15898
15905
15933
16034
16075
16319
16487
16537
16582
16632
16714
17125
17243
17281
17555
17809
18074
18117
18293
18399
18431
18846
18909
19703
21606
22384
22753
24855
25245
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Table S5. Clusters of inhibitors with similar effects in single-batch EMT drug-screen experiment.
Replicate 1
Cluster A
Untreated
control 1
Untreated
control 2
Untreated
control 3
Untreated
control 4
Untreated
control 5
SB431542
(TGFR)

Cluster B
AEE788
(EGFR)
Gefitinib
(EGFR)

Cluster C
PD153035
(EGFR)
PD318088
(MEK12)
WZ8040
(EGFR)

Cluster D
BEZ235
(mTOR)

Cluster E

Cluster F

Cluster G

Cluster H

Cluster I

AZD7762 (Chk)

Bosutinib (Bcr-Abl)
LY2228820
(p38MAPKa)

AT9283 (AuroraK)

TGFb-only control 1

Barasertib (AuroraK)

TGFb-only control 2

Neratinib (HER2)

CYC116 (AuroraK)

TGFb-only control 3

PI-103 (PI3K)
WYE354
(mTOR)
ZSTK474
(PI3K)

Pelitinib (EGFR)

MLN8237 (AuroraK-A)

TGFb-only control 4

Rapamycin (mTOR)

Pazopanib (VEGFR1)

TGFb-only control 5

Temsirolimus (mTOR)
Tie2Kinhibitor (Tie2)

SNS314 (AuroraK-A)
TAE684 (ALK)

AG1024 (IGF-1R)
BGJ398 (FGFR1)
BX912 (PDK-1)
Cediranib (VEGFR)
E7080 (VEGFR2)
Enzastaurin (PKC)
GDC0879 (B-Raf)
GSK690693 (Akt1)
Imatinib (PDGFR)
Linifanib (PDGFRb)
Linsitinib (IGF-1R)
MGCD-265 ( c-MET)
MLN8054 (AuroraK-A)
NVP-ADW742 (IGF-1R)
PHA680632 (AuroraK)
PHT427 (Akt)
Quizartinib (Flt3)
SB216763 (GSK-3a)
SGX523 (HGFR)
TSU68 (VEGFR1)
Tivozanib (VEGFR1)
XL147 (PI3K)
Y-27632 (p160ROCK)
ZM-447439 (AuroraK-A)

Dasatinib (Src)

2
Replicate 2
Cluster A

Cluster B

Cluster C

Cluster D

Untreated control 1

Gefitinib (EGFR)
PD153035
(EGFR)

Neratinib (HER2)

Untreated control 2

AZD7762 (Chk)
PD318088
(MEK12)

Untreated control 3

Tie2Kinhibitor
(Tie2)

Bosutinib (BcrAbl)

Untreated control 4
Untreated control 5
SB431542 (TGFR)

Dasatinib (Src)

Pelitinib (EGFR)
AEE788 (EGFR)

Cluster E
AT9283
(AuroraK)
Barasertib
(AuroraK)
MLN8237
(AuroraKA)
SNS314
(AuroraKA)
BEZ235
(mTOR)

Cluster F
WZ8040
(EGFR)

Cluster G

Cluster H

Cluster I

Cediranib (VEGFR)

AG1024 (IGF-1R)

CYC116 (AuroraK)

BGJ398 (FGFR1)

PI-103 (PI3K)
WYE354
(mTOR)

Linsitinib (IGF-1R)

BX912 (PDK-1)

ZSTK474
(PI3K)

E7080 (VEGFR2)
MGCD-265 (cMET)
MLN8054
(AuroraK-A)
Rapamycin (mTOR)
Temsirolimus
(mTOR)
Tivozanib
(VEGFR1)
TSU68 (VEGFR1)
XL147 (PI3K)

TGFb-only control 1
TGFb-only control 2
TGFb-only control 3
TGFb-only control 4
TGFb-only control 5
Enzastaurin (PKC)
GDC0879 (B-Raf)
GSK690693 (Akt1)
Imatinib (PDGFR)
Linifanib (PDGFRb)
LY2228820
(p38MAPKa)
NVP-ADW742 (IGF1R)
Pazopanib (VEGFR1)
PHA680632 (AuroraK)
PHT427 (Akt)
Quizartinib (Flt3)
SB216763 (GSK-3a)
SGX523 (HGFR)
TAE684 (ALK)
Y-27632 (p160ROCK)
ZM-447439 (AuroraKA)

3
Replicate 3
Cluster A

Cluster B

Cluster C

Cluster D

Cluster E

Cluster F

Cluster G

Untreated control 1

Gefitinib (EGFR)

AEE788 (EGFR)

AT9283 (AuroraK)

Enzastaurin (PKC)

TGFb-only control 1

PI-103 (PI3K)

Untreated control 2

AZD7762 (Chk)

WZ8040 (EGFR)

Barasertib (AuroraK)

Linsitinib (IGF-1R)

TGFb-only control 2

WYE354 (mTOR)

Untreated control 3

PD153035 (EGFR)

Pelitinib (EGFR)

LY2228820 (p38MAPKa)

TGFb-only control 3

ZSTK474 (PI3K)

Untreated control 4

PD318088 (MEK12)

Neratinib (EGFR/HER2)

CYC116 (AuroraK)
MLN8237 (AuroraKA)

MGCD-265 (c-MET)

TGFb-only control 4

Untreated control 5

Tie2Kinhibitor (Tie2)

Bosutinib (Bcr-Abl)

BEZ235 (mTOR)

MLN8054 (AuroraK-A)

TGFb-only control 5

Cediranib (VEGFR)

SNS314 (AuroraK-A)

AG1024 (IGF-1R)

Dasatinib (Src)

Tivozanib (VEGFR1)

BGJ398 (FGFR1)

TSU68 (VEGFR1)

BX912 (PDK-1)

XL147 (PI3K)

E7080 (VEGFR2)

SB431542 (TGFR)

GDC0879 (B-Raf)
GSK690693 (Akt1)
Imatinib (PDGFR)
Linifanib (PDGFRb)
NVP-ADW742 (IGF-1R)
Pazopanib (VEGFR1)
PHA680632 (AuroraK)
PHT427 (Akt)
Quizartinib (Flt3)
Rapamycin (mTOR)
SB216763 (GSK-3a)
SGX523 (HGFR)
TAE684 (ALK)
Temsirolimus (mTOR)
Y-27632 (p160ROCK)
ZM-447439 (AuroraK-A)
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Table S6. Clusters of biospecimens with similar single-cell profiles in melanoma scRNA-seq experiment
Cluster A

Cluster B

Cluster C

Cluster D

Cluster E

Mel53

Mel58

Mel60

Mel67

Mel75

Mel81

Mel65

Mel89

Mel72

Mel82

Mel71

Mel80

Mel84

Mel74

Mel94

Mel88

Mel79
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Table S7. Clusters of biospecimens with similar single-cell profiles in ccRCC mass cytometry experiment
Cluster A

Cluster B

Cluster C

Cluster D

Cluster E

Cluster F

Cluster G

Cluster H

rcc11

rcc12

rcc13

rcc15

rcc16

rcc18

rcc2

rcc55

rcc14

rcc19

rcc26

rcc34

rcc33

rcc20

rcc27

rcc17

rcc24

rcc32

rcc40

rcc35

rcc21

rcc28

rcc36

rcc31

rcc37

rcc41

rcc46

rcc22

rcc29

rcc42

rcc39

rcc4

rcc43

rcc23

rcc30

rcc45

rcc5

rcc59

rcc44

rcc3

rcc38

rcc56

rcc51

rcc64

rcc48

rcc50

rcc75

rcc57

rcc76

rcc65

rcc53

rcc52

rcc81

rcc58

rcc9

rcc54

rcc72

rcc6

rcc60

rcc74

rcc68

rcc62

rcc77

rcc69

rcc63

rcc8

rcc71

rcc67

rcc73

rcc7

rcc80

rcc70
rcc78
rcc79
rcc82

